Relief	O
of	O
cyclin	B-protein
A	I-protein
gene	O
transcriptional	O
inhibition	O
during	O
activation	O
of	O
human	B-cell_type
primary	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
via	O
CD2	B-protein
and	O
CD28	B-protein
adhesion	B-protein
molecules	I-protein
.	O

Cyclin	B-protein
A	I-protein
transcription	O
is	O
cell	O
cycle	O
regulated	O
and	O
induced	O
by	O
cell	O
proliferative	O
signals	O
.	O

To	O
understand	O
the	O
mechanisms	O
underlined	O
in	O
this	O
regulation	O
in	O
normal	O
human	O
cells	O
,	O
we	O
have	O
analysed	O
in	O
vivo	O
protein-DNA	O
interactions	O
at	O
the	O
Cyclin	B-protein
A	I-protein
locus	O
in	O
primary	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Stimulation	O
of	O
purified	O
T	O
lymphocytes	O
by	O
a	O
combination	O
of	O
monoclonal	B-protein
antibodies	I-protein
directed	O
at	O
CD2	B-protein
and	O
CD28	B-protein
adhesion	B-protein
molecules	I-protein
gives	O
rise	O
to	O
a	O
long	O
lasting	O
proliferation	O
in	O
the	O
absence	O
of	O
accessory	B-cell_type
cells	I-cell_type
.	O

Cyclin	B-protein
A	I-protein
was	O
observed	O
after	O
4	O
days	O
of	O
costimulation	O
with	O
anti	B-protein
CD2	I-protein
+	O
CD28	B-protein
whereas	O
stimulation	O
by	O
anti	B-protein
CD2	I-protein
or	O
anti	B-protein
CD28	I-protein
alone	O
was	O
not	O
effective	O
.	O

In	O
vivo	O
genomic	O
DMS	O
footprinting	O
revealed	O
upstream	O
of	O
the	O
major	O
transcription	B-DNA
initiation	I-DNA
sites	I-DNA
,	O
the	O
presence	O
of	O
at	O
least	O
three	O
protein	B-DNA
binding	I-DNA
sites	I-DNA
,	O
two	O
of	O
which	O
were	O
constitutively	O
occupied	O
.	O

They	O
bind	O
in	O
vitro	O
respectively	O
ATF-1	B-protein
and	O
NF-Y	B-protein
proteins	I-protein
.	O

The	O
third	O
site	O
was	O
occupied	O
in	O
quiescent	O
cells	O
or	O
in	O
cells	O
stimulated	O
by	O
anti	B-protein
CD2	I-protein
or	O
anti	B-protein
CD28	I-protein
alone	O
.	O

The	O
mitogenic	O
combination	O
of	O
anti	B-protein
CD2	I-protein
+	O
anti	B-protein
CD28	I-protein
released	O
the	O
footprint	O
as	O
cells	O
were	O
committed	O
to	O
proliferation	O
.	O

Consistent	O
with	O
theses	O
results	O
,	O
nuclear	O
extracts	O
prepared	O
from	O
quiescent	O
cells	O
formed	O
a	O
specific	O
complex	O
with	O
this	O
element	O
,	O
whereas	O
extracts	O
prepared	O
from	O
cells	O
treated	O
with	O
anti	B-protein
CD2	I-protein
+	O
anti	B-protein
CD28	I-protein
failed	O
to	O
do	O
so	O
after	O
cells	O
entered	O
a	O
proliferative	O
state	O
.	O

Oncogene	NULL
(	NULL
1997	NULL
)	NULL
14	NULL
,	NULL
2575-2583	NULL
©	NULL
1997	NULL
Stockton	NULL
Press	NULL
All	NULL
rights	NULL
reserved	NULL
0950-9232/97	NULL
$	NULL
12.00	NULL
Relief	NULL
of	NULL
cyclin	NULL
A	NULL
gene	NULL
transcriptional	NULL
inhibition	NULL
during	NULL
activation	NULL
of	NULL
human	NULL
primary	NULL
T	NULL
lymphocytes	NULL
via	NULL
CD2	NULL
and	NULL
CD28	NULL
adhesion	NULL
molecules	NULL
Ariane	NULL
Plet	NULL
,	NULL
Xavier	NULL
Huet	NULL
,	NULL
Michéle	NULL
Algarté	NULL
,	NULL
Jocelyne	NULL
Rech	NULL
,	NULL
Jean	NULL
Imbert	NULL
,	NULL
Alexandre	NULL
Philips	NULL
and	NULL
Jean	NULL
Marie	NULL
Blanchard	NULL
'Institut	NULL
de	NULL
Génétique	NULL
Moléculaire	NULL
de	NULL
Montpellier	NULL
,	NULL
CNRS	NULL
,	NULL
UMR	NULL
5535	NULL
,	NULL
BP	NULL
5051	NULL
,	NULL
1919	NULL
route	NULL
de	NULL
Mende	NULL
,	NULL
34033	NULL
Montpellier	NULL
cedex	NULL
1	NULL
,	NULL
France	NULL
;	NULL
INSERM	NULL
U119	NULL
,	NULL
27	NULL
Boulevard	NULL
Lei	NULL
Roure	NULL
,	NULL
13009	NULL
Marseille	NULL
,	NULL
France	NULL
Cyclin	NULL
A	NULL
transcription	NULL
is	NULL
cell	NULL
cycle	NULL
regulated	NULL
and	NULL
induced	NULL
by	NULL
cell	NULL
proliferative	NULL
signals	NULL
.	NULL

To	NULL
understand	NULL
the	NULL
mechanisms	NULL
underlined	NULL
in	NULL
this	NULL
regulation	NULL
in	NULL
normal	NULL
human	NULL
cells	NULL
,	NULL
we	NULL
have	NULL
analysed	NULL
in	NULL
vivo	NULL
protein-DNA	NULL
interactions	NULL
at	NULL
the	NULL
Cyclin	NULL
A	NULL
locus	NULL
in	NULL
primary	NULL
T	NULL
lymphocytes	NULL
.	NULL

Stimulation	NULL
of	NULL
purified	NULL
T	NULL
lymphocytes	NULL
by	NULL
a	NULL
combination	NULL
of	NULL
monoclonal	NULL
antibodies	NULL
directed	NULL
at	NULL
CD2	NULL
and	NULL
CD28	NULL
adhesion	NULL
molecules	NULL
gives	NULL
rise	NULL
to	NULL
a	NULL
long	NULL
lasting	NULL
proliferation	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
accessory	NULL
cells	NULL
.	NULL

Cyclin	NULL
A	NULL
was	NULL
observed	NULL
after	NULL
4	NULL
days	NULL
of	NULL
costimulation	NULL
with	NULL
anti	NULL
CD2	NULL
+	NULL
CD28	NULL
whereas	NULL
stimulation	NULL
by	NULL
anti	NULL
CD2	NULL
or	NULL
anti	NULL
CD28	NULL
alone	NULL
was	NULL
not	NULL
effective	NULL
.	NULL

In	NULL
vivo	NULL
genomic	NULL
DMS	NULL
footprinting	NULL
revealed	NULL
upstream	NULL
of	NULL
the	NULL
major	NULL
transcription	NULL
initiation	NULL
sites	NULL
,	NULL
the	NULL
presence	NULL
of	NULL
at	NULL
least	NULL
three	NULL
protein	NULL
binding	NULL
sites	NULL
,	NULL
two	NULL
of	NULL
which	NULL
were	NULL
constitutively	NULL
occupied	NULL
.	NULL

They	NULL
bind	NULL
in	NULL
vitro	NULL
respectively	NULL
ATF-1	NULL
and	NULL
NF-Y	NULL
proteins	NULL
.	NULL

The	NULL
third	NULL
site	NULL
was	NULL
occupied	NULL
in	NULL
quiescent	NULL
cells	NULL
or	NULL
in	NULL
cells	NULL
stimulated	NULL
by	NULL
anti	NULL
CD2	NULL
or	NULL
anti	NULL
CD28	NULL
alone	NULL
.	NULL

The	NULL
mitogenic	NULL
combination	NULL
of	NULL
anti	NULL
CD2	NULL
+	NULL
anti	NULL
CD28	NULL
released	NULL
the	NULL
footprint	NULL
as	NULL
cells	NULL
were	NULL
committed	NULL
to	NULL
proliferation	NULL
.	NULL

Consistent	NULL
with	NULL
theses	NULL
results	NULL
,	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
quiescent	NULL
cells	NULL
formed	NULL
a	NULL
specific	NULL
complex	NULL
with	NULL
this	NULL
element	NULL
,	NULL
whereas	NULL
extracts	NULL
prepared	NULL
from	NULL
cells	NULL
treated	NULL
with	NULL
anti	NULL
CD2	NULL
+	NULL
anti	NULL
CD28	NULL
failed	NULL
to	NULL
do	NULL
so	NULL
after	NULL
cells	NULL
entered	NULL
a	NULL
proliferative	NULL
state	NULL
.	NULL

Keywords	NULL
:	NULL
cyclin	NULL
A	NULL
;	NULL
primary	NULL
T	NULL
lymphocytes	NULL
adhesion	NULL
Introduction	NULL
The	NULL
mechanisms	NULL
leading	NULL
to	NULL
transcriptional	NULL
modulation	NULL
of	NULL
proliferation	NULL
associated	NULL
genes	NULL
involved	NULL
in	NULL
the	NULL
control	NULL
of	NULL
the	NULL
transition	NULL
between	NULL
the	NULL
G	NULL
,	NULL
and	NULL
the	NULL
S	NULL
phases	NULL
of	NULL
the	NULL
cell	NULL
division	NULL
cycle	NULL
are	NULL
not	NULL
well	NULL
understood	NULL
in	NULL
primary	NULL
cells	NULL
.	NULL

Only	NULL
few	NULL
informations	NULL
have	NULL
been	NULL
gathered	NULL
about	NULL
cell	NULL
cycle	NULL
specific	NULL
binding	NULL
of	NULL
transcription	NULL
factors	NULL
in	NULL
vivo	NULL
.	NULL

We	NULL
have	NULL
undertaken	NULL
a	NULL
thorough	NULL
analysis	NULL
of	NULL
the	NULL
in	NULL
vivo	NULL
structure	NULL
of	NULL
the	NULL
promoter-proximal	NULL
region	NULL
of	NULL
cyclin	NULL
A	NULL
gene	NULL
through	NULL
the	NULL
use	NULL
of	NULL
high	NULL
resolution	NULL
genomic	NULL
footprinting	NULL
.	NULL

It	NULL
is	NULL
now	NULL
currently	NULL
proposed	NULL
that	NULL
cell	NULL
progression	NULL
through	NULL
the	NULL
different	NULL
phases	NULL
of	NULL
the	NULL
cell	NULL
division	NULL
cycle	NULL
is	NULL
controlled	NULL
by	NULL
a	NULL
family	NULL
of	NULL
cyclin-dependent	NULL
protein	NULL
kinases	NULL
(	NULL
cdk	NULL
)	NULL
.	NULL

Several	NULL
types	NULL
of	NULL
cyclins	NULL
have	NULL
been	NULL
identified	NULL
in	NULL
higher	NULL
eukaryotes	NULL
and	NULL
cyclin	NULL
A	NULL
is	NULL
synthesized	NULL
at	NULL
the	NULL
onset	NULL
of	NULL
DNA	NULL
replication	NULL
as	NULL
well	NULL
as	NULL
during	NULL
the	NULL
G	NULL
,	NULL
/M	NULL
transition	NULL
.	NULL

By	NULL
binding	NULL
to	NULL
respectively	NULL
Correspondence	NULL
:	NULL
JM	NULL
Blanchard	NULL
Received	NULL
7	NULL
November	NULL
1996	NULL
;	NULL
revised	NULL
14	NULL
February	NULL
1997	NULL
;	NULL
accepted	NULL
17	NULL
February	NULL
1997	NULL
the	NULL
cdk2	NULL
and	NULL
cdc2	NULL
(	NULL
ecdk1	NULL
)	NULL
kinases	NULL
,	NULL
the	NULL
A-type	NULL
cyclin	NULL
has	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
control	NULL
of	NULL
both	NULL
the	NULL
dependence	NULL
of	NULL
mitosis	NULL
on	NULL
S-phase	NULL
completion	NULL
,	NULL
as	NULL
well	NULL
as	NULL
that	NULL
of	NULL
mitosis	NULL
(	NULL
Swenson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
;	NULL
Lehner	NULL
and	NULL
O'Farrell	NULL
,	NULL
1989	NULL
,	NULL
1990	NULL
;	NULL
Pines	NULL
and	NULL
Hunter	NULL
,	NULL
1990a	NULL
;	NULL
Tsai	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
,	NULL
Walker	NULL
and	NULL
Maller	NULL
,	NULL
1991	NULL
)	NULL
.	NULL

Cyclin	NULL
A	NULL
is	NULL
found	NULL
in	NULL
cellular	NULL
activities	NULL
which	NULL
promote	NULL
both	NULL
replication	NULL
(	NULL
Cardoso	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
D'Urso	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Pagano	NULL
et	NULL
al	NULL
.	NULL

,	NULL
19922	NULL
;	NULL
Pines	NULL
and	NULL
Hunter	NULL
,	NULL
1990b	NULL
;	NULL
Resnitzky	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Sobczak-Thepot	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
,	NULL
and	NULL
transcription	NULL
(	NULL
for	NULL
reviews	NULL
see	NULL
:	NULL
LaThangue	NULL
,	NULL
1994	NULL
;	NULL
Nevins	NULL
,	NULL
1992	NULL
;	NULL
Weinberg	NULL
,	NULL
1995	NULL
)	NULL
.	NULL

In	NULL
the	NULL
former	NULL
case	NULL
,	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
associated	NULL
with	NULL
replication	NULL
complexes	NULL
and	NULL
is	NULL
likely	NULL
to	NULL
directly	NULL
participate	NULL
in	NULL
the	NULL
phosphorylation	NULL
of	NULL
some	NULL
of	NULL
the	NULL
replication	NULL
factors	NULL
(	NULL
Dutta	NULL
&	NULL
Stillman	NULL
,	NULL
1992	NULL
;	NULL
Xiong	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

In	NULL
the	NULL
latter	NULL
case	NULL
,	NULL
its	NULL
association	NULL
with	NULL
the	NULL
E2F/DRTFI	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
has	NULL
been	NULL
proposed	NULL
to	NULL
play	NULL
a	NULL
central	NULL
role	NULL
in	NULL
cell	NULL
cycle	NULL
transcriptional	NULL
control	NULL
(	NULL
LaThangue	NULL
,	NULL
1994	NULL
)	NULL
.	NULL

A	NULL
large	NULL
body	NULL
of	NULL
evidence	NULL
suggests	NULL
that	NULL
cyclin-dependent	NULL
kinases	NULL
participate	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
activity	NULL
of	NULL
this	NULL
transcription	NULL
complex	NULL
.	NULL

This	NULL
is	NULL
believed	NULL
to	NULL
occur	NULL
either	NULL
directly	NULL
,	NULL
by	NULL
the	NULL
phosphorylation	NULL
of	NULL
E2F	NULL
by	NULL
cyclin	NULL
A-cdk2	NULL
kinase	NULL
,	NULL
or	NULL
indirectly	NULL
through	NULL
the	NULL
phosphorylation	NULL
of	NULL
a	NULL
group	NULL
of	NULL
proteins	NULL
structurally	NULL
related	NULL
to	NULL
RB	NULL
,	NULL
the	NULL
retinoblastoma	NULL
susceptibility	NULL
gene	NULL
product	NULL
,	NULL
by	NULL
cyclins	NULL
D	NULL
,	NULL
E	NULL
,	NULL
A	NULL
associated	NULL
with	NULL
edk4	NULL
,	NULL
edk6	NULL
or	NULL
cedk2	NULL
kinases	NULL
.	NULL

Consistent	NULL
with	NULL
these	NULL
ideas	NULL
,	NULL
cyclin	NULL
A	NULL
is	NULL
found	NULL
complexed	NULL
with	NULL
E2F	NULL
in	NULL
late	NULL
G	NULL
,	NULL
and	NULL
during	NULL
S	NULL
phases	NULL
,	NULL
recruiting	NULL
the	NULL
catalytic	NULL
kinase	NULL
subunit	NULL
to	NULL
the	NULL
DNA-binding	NULL
complex	NULL
(	NULL
Cao	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
Devoto	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
Helin	NULL
and	NULL
Harlow	NULL
,	NULL
1993	NULL
;	NULL
Li	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Pagano	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992b	NULL
;	NULL
Shirodkar	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
Xu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
the	NULL
expanding	NULL
wealth	NULL
of	NULL
information	NULL
about	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
expression	NULL
of	NULL
molecules	NULL
involved	NULL
in	NULL
cell	NULL
cycle	NULL
control	NULL
in	NULL
established	NULL
cell	NULL
lines	NULL
,	NULL
only	NULL
few	NULL
studies	NULL
have	NULL
been	NULL
devoted	NULL
to	NULL
normal	NULL
human	NULL
primary	NULL
cells	NULL
.	NULL

Primary	NULL
T	NULL
cell	NULL
culture	NULL
offers	NULL
a	NULL
good	NULL
opportunity	NULL
to	NULL
study	NULL
the	NULL
transition	NULL
from	NULL
a	NULL
quiescent	NULL
to	NULL
a	NULL
proliferative	NULL
state	NULL
upon	NULL
peripheral	NULL
stimulation	NULL
.	NULL

These	NULL
cells	NULL
,	NULL
which	NULL
are	NULL
normally	NULL
in	NULL
a	NULL
G	NULL
,	NULL
state	NULL
,	NULL
can	NULL
be	NULL
quantitatively	NULL
committed	NULL
to	NULL
proliferation	NULL
when	NULL
receiving	NULL
an	NULL
appropriate	NULL
combination	NULL
of	NULL
mitogenic	NULL
stimuli	NULL
such	NULL
as	NULL
CD28-specific	NULL
monoclonal	NULL
antibodies	NULL
(	NULL
mAbs	NULL
)	NULL
in	NULL
association	NULL
with	NULL
either	NULL
CD2	NULL
or	NULL
CD3	NULL
mAbs	NULL
.	NULL

Under	NULL
such	NULL
circumstances	NULL
,	NULL
several	NULL
of	NULL
the	NULL
physiological	NULL
aspects	NULL
of	NULL
T	NULL
lymphocyte	NULL
activation	NULL
are	NULL
mimicked	NULL
.	NULL

CD2	NULL
+	NULL
CD28	NULL
costimulation	NULL
induces	NULL
a	NULL
strong	NULL
activation	NULL
of	NULL
both	NULL
IL-2Ra	NULL
gene	NULL
transcription	NULL
and	NULL
mRNA	NULL
stabilization	NULL
,	NULL
which	NULL
results	NULL
in	NULL
the	NULL
high	NULL
level	NULL
of	NULL
expression	NULL
of	NULL
the	NULL
receptor	NULL
at	NULL
the	NULL
cell	NULL
surface	NULL
.	NULL

This	NULL
is	NULL
followed	NULL
by	NULL
a	NULL
wave	NULL
of	NULL
cell	NULL
divisions	NULL
after	NULL
a	NULL
3-4	NULL
days	NULL
time	NULL
lag	NULL
,	NULL
responsible	NULL
for	NULL
a	NULL
long	NULL
lasting	NULL
(	NULL
3-4	NULL
weeks	NULL
)	NULL
and	NULL
monocyte-independent	NULL
T	NULL
Cyclin	NULL
A	NULL
expression	NULL
in	NULL
human	NULL
primary	NULL
T	NULL
lymphocytes	NULL
A	NULL
Plet	NULL
et	NULL
al	NULL
2576	NULL
cell	NULL
proliferation	NULL
.	NULL

This	NULL
is	NULL
associated	NULL
with	NULL
the	NULL
prolonged	NULL
secretion	NULL
of	NULL
cytokines	NULL
,	NULL
either	NULL
T-specific	NULL
,	NULL
such	NULL
as	NULL
IL-2	NULL
and	NULL
IFN-y	NULL
,	NULL
or	NULL
normally	NULL
synthesized	NULL
by	NULL
accessory	NULL
cells	NULL
,	NULL
such	NULL
as	NULL
IL-1	NULL
@	NULL
,	NULL
TNF-	NULL
«	NULL
and	NULL
CSF-1	NULL
(	NULL
Olive	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

It	NULL
had	NULL
previously	NULL
been	NULL
shown	NULL
that	NULL
cyclin	NULL
A	NULL
gene	NULL
was	NULL
transcriptionally	NULL
activated	NULL
by	NULL
mitogenic	NULL
signals	NULL
and	NULL
the	NULL
major	NULL
promoter-proximal	NULL
elements	NULL
characterized	NULL
by	NULL
transient	NULL
transfection	NULL
experiments	NULL
into	NULL
transformed	NULL
or	NULL
immortalized	NULL
cell	NULL
lines	NULL
(	NULL
Barlat	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Henglein	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Schulze	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Zwicker	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Huet	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

Using	NULL
dimethylsulphate	NULL
(	NULL
DMS	NULL
)	NULL
genomic	NULL
footprinting	NULL
we	NULL
show	NULL
here	NULL
that	NULL
,	NULL
like	NULL
for	NULL
the	NULL
established	NULL
cell	NULL
lines	NULL
examined	NULL
so	NULL
far	NULL
,	NULL
at	NULL
least	NULL
three	NULL
putative	NULL
protein	NULL
binding	NULL
sites	NULL
are	NULL
occupied	NULL
in	NULL
vivo	NULL
.	NULL

Two	NULL
of	NULL
them	NULL
,	NULL
which	NULL
bind	NULL
in	NULL
vitro	NULL
proteins	NULL
of	NULL
the	NULL
CREB/	NULL
ATF	NULL
and	NULL
NF-Y	NULL
families	NULL
,	NULL
are	NULL
constitutively	NULL
occupied	NULL
in	NULL
vivo	NULL
.	NULL

The	NULL
third	NULL
site	NULL
,	NULL
proposed	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
down	NULL
regulation	NULL
of	NULL
the	NULL
promoter	NULL
in	NULL
quiescent	NULL
cells	NULL
,	NULL
is	NULL
occupied	NULL
in	NULL
quiescent	NULL
but	NULL
not	NULL
in	NULL
CD2+CD28	NULL
costimulated	NULL
proliferating	NULL
cells	NULL
.	NULL

Stimulations	NULL
by	NULL
either	NULL
CD2	NULL
or	NULL
CD28	NULL
mAbs	NULL
alone	NULL
,	NULL
conditions	NULL
known	NULL
to	NULL
be	NULL
insufficient	NULL
to	NULL
give	NULL
rise	NULL
to	NULL
a	NULL
mitogenic	NULL
signal	NULL
,	NULL
did	NULL
not	NULL
result	NULL
in	NULL
a	NULL
relief	NULL
of	NULL
the	NULL
footprint	NULL
.	NULL

Results	NULL
Cyclin	NULL
A	NULL
expression	NULL
in	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
When	NULL
purified	NULL
T	NULL
lymphocytes	NULL
were	NULL
stimulated	NULL
with	NULL
a	NULL
combination	NULL
of	NULL
anti	NULL
CD2	NULL
+	NULL
anti	NULL
CD28	NULL
mAbs	NULL
,	NULL
incorporation	NULL
of	NULL
radioactive	NULL
thymidine	NULL
was	NULL
observed	NULL
after	NULL
a	NULL
1	NULL
day	NULL
time	NULL
lag	NULL
and	NULL
increased	NULL
rapidly	NULL
to	NULL
reach	NULL
a	NULL
maximum	NULL
around	NULL
8-10	NULL
days	NULL
of	NULL
costimulation	NULL
(	NULL
Figure	NULL
la	NULL
)	NULL
.	NULL

This	NULL
resulted	NULL
in	NULL
a	NULL
more	NULL
than	NULL
10-fold	NULL
increase	NULL
in	NULL
cell	NULL
number	NULL
(	NULL
Figure	NULL
1c	NULL
)	NULL
which	NULL
was	NULL
spread	NULL
on	NULL
a	NULL
3-4	NULL
week	NULL
period	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
stimulation	NULL
by	NULL
anti	NULL
CD2	NULL
or	NULL
anti	NULL
CD28	NULL
mAb	NULL
alone	NULL
did	NULL
not	NULL
give	NULL
rise	NULL
to	NULL
a	NULL
measurable	NULL
level	NULL
of	NULL
thymidine	NULL
incorporation	NULL
(	NULL
Figure	NULL
1b	NULL
)	NULL
,	NULL
nor	NULL
to	NULL
an	NULL
increase	NULL
in	NULL
cell	NULL
number	NULL
.	NULL

Similarly	NULL
,	NULL
CD2+CD28	NULL
costimulation	NULL
activated	NULL
the	NULL
secretion	NULL
of	NULL
IL-2	NULL
which	NULL
peaked	NULL
around	NULL
4	NULL
days	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
expression	NULL
of	NULL
IL-2Ra	NULL
chain	NULL
of	NULL
the	NULL
receptor	NULL
at	NULL
the	NULL
cell	NULL
surface	NULL
,	NULL
which	NULL
lasted	NULL
for	NULL
at	NULL
least	NULL
3	NULL
weeks	NULL
,	NULL
with	NULL
more	NULL
than	NULL
80	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
scoring	NULL
positive	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
,	NULL
Costello	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

Medium	NULL
alone	NULL
,	NULL
single	NULL
anti	NULL
CD2	NULL
or	NULL
anti	NULL
CD28	NULL
stimulations	NULL
,	NULL
were	NULL
ineffective	NULL
in	NULL
inducing	NULL
a	NULL
detectable	NULL
level	NULL
of	NULL
secreted	NULL
IL-2	NULL
,	NULL
neither	NULL
an	NULL
increase	NULL
of	NULL
IL-2R	NULL
«	NULL
chain	NULL
at	NULL
the	NULL
cell	NULL
surface	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Cyclin	NULL
A	NULL
expression	NULL
was	NULL
monitored	NULL
by	NULL
a	NULL
Western	NULL
blot	NULL
analysis	NULL
of	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
either	NULL
quiescent	NULL
or	NULL
stimulated	NULL
T	NULL
lymphocytes	NULL
.	NULL

In	NULL
a	NULL
way	NULL
parallel	NULL
to	NULL
that	NULL
of	NULL
radioactive	NULL
thymidine	NULL
incorporation	NULL
,	NULL
the	NULL
protein	NULL
began	NULL
to	NULL
be	NULL
detectable	NULL
after	NULL
2	NULL
days	NULL
of	NULL
CD2+CD28	NULL
costimulation	NULL
,	NULL
was	NULL
clearly	NULL
visible	NULL
at	NULL
4	NULL
days	NULL
,	NULL
and	NULL
its	NULL
accumulation	NULL
was	NULL
maximum	NULL
between	NULL
12	NULL
and	NULL
14	NULL
days	NULL
(	NULL
Figure	NULL
1d	NULL
)	NULL
.	NULL

Again	NULL
,	NULL
medium	NULL
alone	NULL
,	NULL
anti	NULL
CD2	NULL
or	NULL
anti	NULL
CD28	NULL
single	NULL
stimulations	NULL
were	NULL
ineffective	NULL
in	NULL
inducing	NULL
cyclin	NULL
A	NULL
.	NULL

A	NULL
motif	NULL
required	NULL
for	NULL
the	NULL
repression	NULL
of	NULL
cyclin	NULL
A	NULL
promoter	NULL
in	NULL
quiescent	NULL
fibroblasts	NULL
is	NULL
active	NULL
in	NULL
a	NULL
T	NULL
cell	NULL
context	NULL
It	NULL
has	NULL
previously	NULL
been	NULL
shown	NULL
that	NULL
cyclin	NULL
A	NULL
expression	NULL
during	NULL
the	NULL
G1/S	NULL
transition	NULL
results	NULL
from	NULL
a	NULL
transcriptional	NULL
activation	NULL
of	NULL
its	NULL
gene	NULL
(	NULL
Barlat	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Bie	NULL
b	NULL
CD2+28	NULL
@	NULL
e	NULL
A	NULL
.	NULL

.~	NULL
P	NULL
u	NULL
©	NULL
AJ	NULL
Clo	NULL
4	NULL
days	NULL
£	NULL
8	NULL
<	NULL
5	NULL
E7	NULL
1	NULL
2	NULL
7	NULL
&	NULL
o	NULL
_	NULL
chr	NULL
CDS	NULL
R	NULL
=	NULL
ha	NULL
rse	NULL
<	NULL
,	NULL
10	NULL
x	NULL
4	NULL
is	NULL
3	NULL
M	NULL
0	NULL
4	NULL
8	NULL
12	NULL
16	NULL
days	NULL
d	NULL
MW	NULL
(	NULL
kD	NULL
)	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
96	NULL
64	NULL
-	NULL
ln	NULL
-	NULL
eer	NULL
46	NULL
days	NULL
in	NULL
culture	NULL
0	NULL
4	NULL
1	NULL
4	NULL
14	NULL
«	NULL
CD2	NULL
+	NULL
«	NULL
CD28	NULL
0	NULL
-	NULL
+	NULL
+	NULL
+	NULL
Figure	NULL
1	NULL
Induction	NULL
of	NULL
T	NULL
lymphocyte	NULL
proliferation	NULL
and	NULL
cyclin	NULL
A	NULL
by	NULL
the	NULL
costimulation	NULL
with	NULL
monoclonal	NULL
antibodies	NULL
anti	NULL
CD2	NULL
and	NULL
anti	NULL
CD28	NULL
.	NULL

(	NULL
a	NULL
)	NULL
DNA	NULL
synthesis	NULL
in	NULL
stimulated	NULL
T	NULL
lymphocytes	NULL
.	NULL

[	NULL
HIJthymidine	NULL
incorporation	NULL
was	NULL
measured	NULL
in	NULL
cells	NULL
treated	NULL
with	NULL
antibodies	NULL
for	NULL
the	NULL
time	NULL
indicated	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
methods	NULL
.	NULL

(	NULL
b	NULL
)	NULL
3H-thymidine	NULL
incorporation	NULL
measured	NULL
after	NULL
4	NULL
days	NULL
in	NULL
absence	NULL
(	NULL
0	NULL
)	NULL
or	NULL
in	NULL
presence	NULL
of	NULL
single	NULL
(	NULL
CD2	NULL
,	NULL
CD28	NULL
)	NULL
or	NULL
double	NULL
(	NULL
CD2+28	NULL
)	NULL
stimulation	NULL
.	NULL

(	NULL
¢	NULL
)	NULL
Growth	NULL
curve	NULL
of	NULL
T	NULL
cells	NULL
induced	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
both	NULL
antibodies	NULL
.	NULL

(	NULL
d	NULL
)	NULL
Immunoblot	NULL
analysis	NULL
of	NULL
protein	NULL
lysates	NULL
prepared	NULL
from	NULL
cells	NULL
either	NULL
newly	NULL
purified	NULL
from	NULL
peripheral	NULL
blood	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
cultured	NULL
in	NULL
absence	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
or	NULL
in	NULL
presence	NULL
of	NULL
the	NULL
proliferative	NULL
monoclonal	NULL
antibodies	NULL
for	NULL
the	NULL
time	NULL
indicated	NULL
(	NULL
lanes	NULL
3-5	NULL
)	NULL
Henglein	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Schulze	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Zwicker	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Huet	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

Comparison	NULL
of	NULL
both	NULL
the	NULL
human	NULL
and	NULL
mouse	NULL
cyclin	NULL
A	NULL
promoters	NULL
has	NULL
revealed	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
stretch	NULL
of	NULL
conserved	NULL
nucleotides	NULL
within	NULL
which	NULL
several	NULL
putative	NULL
protein	NULL
binding	NULL
sites	NULL
have	NULL
been	NULL
underlined	NULL
.	NULL

Several	NULL
recent	NULL
reports	NULL
,	NULL
based	NULL
on	NULL
transient	NULL
transfection	NULL
experiments	NULL
carried	NULL
out	NULL
in	NULL
immortalized	NULL
or	NULL
transformed	NULL
cell	NULL
lines	NULL
have	NULL
stressed	NULL
the	NULL
importance	NULL
of	NULL
a	NULL
cyclic	NULL
AMP	NULL
responsive	NULL
element	NULL
(	NULL
CRE	NULL
)	NULL
in	NULL
mediating	NULL
cyclin	NULL
A	NULL
gene	NULL
responses	NULL
to	NULL
both	NULL
cAMP	NULL
,	NULL
TGF-	NULL
$	NULL
or	NULL
contact	NULL
inhibition	NULL
in	NULL
human	NULL
Hs27	NULL
(	NULL
Desdouets	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
,	NULL
hamster	NULL
CCL39	NULL
fibroblasts	NULL
(	NULL
Barlat	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
in	NULL
bovine	NULL
aortic	NULL
endothelial	NULL
cells	NULL
(	NULL
BAEC	NULL
)	NULL
(	NULL
Yoshizumi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
another	NULL
GC-rich	NULL
element	NULL
,	NULL
named	NULL
the	NULL
'cell	NULL
cycle	NULL
responsive	NULL
element	NULL
'	NULL
(	NULL
CCRE	NULL
)	NULL
has	NULL
also	NULL
been	NULL
demonstrated	NULL
to	NULL
be	NULL
instrumental	NULL
in	NULL
the	NULL
response	NULL
of	NULL
cyclin	NULL
A	NULL
promoter	NULL
to	NULL
serum	NULL
stimulation	NULL
in	NULL
quiescent	NULL
fibroblasts	NULL
(	NULL
Huet	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

Mutation	NULL
of	NULL
this	NULL
site	NULL
rendered	NULL
the	NULL
cyclin	NULL
A	NULL
promoter	NULL
constitutive	NULL
and	NULL
cell	NULL
cycle-irresponsive	NULL
.	NULL

In	NULL
order	NULL
to	NULL
confirm	NULL
this	NULL
observation	NULL
in	NULL
T	NULL
lymphocytes	NULL
,	NULL
we	NULL
resorted	NULL
to	NULL
the	NULL
use	NULL
of	NULL
a	NULL
human	NULL
T	NULL
cell	NULL
line	NULL
(	NULL
Kit225	NULL
)	NULL
which	NULL
recapitulates	NULL
some	NULL
of	NULL
the	NULL
properties	NULL
of	NULL
normal	NULL
T	NULL
lymphocytes	NULL
,	NULL
but	NULL
which	NULL
are	NULL
more	NULL
amenable	NULL
to	NULL
transfection	NULL
experiments	NULL
.	NULL

Purified	NULL
,	NULL
quiescent	NULL
primary	NULL
T	NULL
lymphocytes	NULL
turned	NULL
out	NULL
to	NULL
be	NULL
,	NULL
at	NULL
least	NULL
in	NULL
our	NULL
hands	NULL
,	NULL
very	NULL
difficult	NULL
to	NULL
transfect	NULL
,	NULL
and	NULL
only	NULL
strong	NULL
promoters	NULL
such	NULL
as	NULL
the	NULL
human	NULL
cytomegalovirus	NULL
early	NULL
promoter	NULL
gave	NULL
reproducible	NULL
results	NULL
.	NULL

Kit225	NULL
cells	NULL
are	NULL
absolutely	NULL
dependent	NULL
upon	NULL
the	NULL
presence	NULL
of	NULL
IL-2	NULL
for	NULL
their	NULL
proliferation	NULL
.	NULL

This	NULL
is	NULL
illustrated	NULL
in	NULL
Figure	NULL
2a	NULL
where	NULL
cells	NULL
grown	NULL
in	NULL
serum	NULL
alone	NULL
(	NULL
upper	NULL
panel	NULL
)	NULL
or	NULL
serum	NULL
+	NULL
IL-2	NULL
(	NULL
lower	NULL
panel	NULL
)	NULL
have	NULL
been	NULL
sorted	NULL
according	NULL
to	NULL
their	NULL
DNA	NULL
content	NULL
.	NULL

In	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
cytokine	NULL
almost	NULL
80	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
were	NULL
found	NULL
in	NULL
the	NULL
G	NULL
,	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
,	NULL
with	NULL
only	NULL
few	NULL
cells	NULL
entering	NULL
S	NULL
phase	NULL
(	NULL
6.4	NULL
%	NULL
)	NULL
.	NULL

IL-2	NULL
treatment	NULL
gave	NULL
rise	NULL
to	NULL
a	NULL
five-	NULL
to	NULL
sixfold	NULL
increase	NULL
in	NULL
cells	NULL
in	NULL
the	NULL
S	NULL
phase	NULL
(	NULL
35.8	NULL
%	NULL
)	NULL
together	NULL
with	NULL
a	NULL
twofold	NULL
increase	NULL
in	NULL
cells	NULL
in	NULL
the	NULL
G2/M	NULL
phase	NULL
(	NULL
28.7	NULL
%	NULL
)	NULL
.	NULL

Kit225	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
a	NULL
luciferase	NULL
expression	NULL
vector	NULL
containing	NULL
a	NULL
DNA	NULL
fragment	NULL
spanning	NULL
nucleotides	NULL
-177	NULL
to	NULL
+100	NULL
relative	NULL
to	NULL
the	NULL
3	NULL
most	NULL
initiation	NULL
site	NULL
(	NULL
Barlat	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Huet	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

Stimulation	NULL
of	NULL
quiescent	NULL
cells	NULL
by	NULL
IL-2	NULL
gave	NULL
rise	NULL
to	NULL
a	NULL
four-	NULL
to	NULL
fivefold	NULL
stimulation	NULL
of	NULL
the	NULL
wild	NULL
type	NULL
vector	NULL
(	NULL
pGL2-cycA	NULL
)	NULL
,	NULL
a	NULL
figure	NULL
commensurate	NULL
with	NULL
the	NULL
increase	NULL
in	NULL
S	NULL
phase	NULL
cells	NULL
,	NULL
whereas	NULL
mutation	NULL
of	NULL
the	NULL
CCRE	NULL
(	NULL
pGL2-cycAm	NULL
)	NULL
abolished	NULL
this	NULL
effect	NULL
(	NULL
Figure	NULL
2b	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
most	NULL
of	NULL
this	NULL
effect	NULL
was	NULL
accounted	NULL
for	NULL
by	NULL
a	NULL
relief	NULL
of	NULL
the	NULL
inhibition	NULL
observed	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
IL-2	NULL
.	NULL

An	NULL
in	NULL
vivo	NULL
footprint	NULL
is	NULL
present	NULL
on	NULL
a	NULL
motif	NULL
involved	NULL
in	NULL
cell	NULL
cycle	NULL
control	NULL
of	NULL
cyclin	NULL
A	NULL
promoter	NULL
only	NULL
in	NULL
quiescent	NULL
T	NULL
lymphocytes	NULL
To	NULL
analyse	NULL
in	NULL
more	NULL
details	NULL
the	NULL
mechanism	NULL
governing	NULL
the	NULL
inducibility	NULL
of	NULL
cyclin	NULL
A	NULL
gene	NULL
transcription	NULL
,	NULL
we	NULL
performed	NULL
an	NULL
in	NULL
vivo	NULL
footprint	NULL
analysis	NULL
of	NULL
the	NULL
region	NULL
containing	NULL
the	NULL
conserved	NULL
upstream	NULL
promoter	NULL
sequence	NULL
.	NULL

Quiescent	NULL
primary	NULL
T	NULL
lymphocytes	NULL
were	NULL
either	NULL
stimulated	NULL
with	NULL
anti	NULL
CD2	NULL
,	NULL
anti	NULL
CD28	NULL
or	NULL
a	NULL
combination	NULL
of	NULL
both	NULL
mAbs	NULL
.	NULL

At	NULL
each	NULL
indicated	NULL
time	NULL
of	NULL
treatment	NULL
,	NULL
cells	NULL
were	NULL
exposed	NULL
to	NULL
dimethylsulphate	NULL
(	NULL
DMS	NULL
)	NULL
and	NULL
genomic	NULL
DNA	NULL
was	NULL
processed	NULL
for	NULL
the	NULL
detection	NULL
of	NULL
hypomethy-lated	NULL
guanine	NULL
residues	NULL
as	NULL
described	NULL
(	NULL
Garrity	NULL
and	NULL
Wold	NULL
,	NULL
1992	NULL
;	NULL
Barlat	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

In	NULL
cells	NULL
either	NULL
quiescent	NULL
or	NULL
stimulated	NULL
for	NULL
a	NULL
24	NULL
h	NULL
period	NULL
(	NULL
Figure	NULL
3a	NULL
,	NULL
left	NULL
panel	NULL
)	NULL
with	NULL
any	NULL
combination	NULL
of	NULL
mAbs	NULL
,	NULL
a	NULL
clear	NULL
protection	NULL
was	NULL
visible	NULL
on	NULL
both	NULL
the	NULL
CRE	NULL
and	NULL
the	NULL
GC-rich	NULL
(	NULL
CCRE	NULL
)	NULL
motifs	NULL
together	NULL
with	NULL
a	NULL
weaker	NULL
but	NULL
significant	NULL
protection	NULL
of	NULL
a	NULL
NF-Y	NULL
site	NULL
(	NULL
Figure	NULL
3a	NULL
)	NULL
.	NULL

As	NULL
a	NULL
control	NULL
that	NULL
lymphocytes	NULL
have	NULL
already	NULL
evolved	NULL
towards	NULL
prolifera-tion	NULL
,	NULL
changes	NULL
in	NULL
proteins	NULL
binding	NULL
to	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
present	NULL
in	NULL
the	NULL
promoter	NULL
of	NULL
the	NULL
early	NULL
gene	NULL
coding	NULL
for	NULL
IL-2Ra	NULL
«	NULL
was	NULL
examined	NULL
on	NULL
the	NULL
same	NULL
DNA	NULL
preparations	NULL
(	NULL
Figure	NULL
4	NULL
)	NULL
.	NULL

A	NULL
clear	NULL
protection	NULL
was	NULL
observed	NULL
as	NULL
soon	NULL
as	NULL
6	NULL
h	NULL
post	NULL
costimulation	NULL
which	NULL
corresponded	NULL
to	NULL
nuclear	NULL
translocation	NULL
of	NULL
NF-xB	NULL
as	NULL
detected	NULL
by	NULL
gel	NULL
shift	NULL
experiments	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
(	NULL
Algarte	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

However	NULL
,	NULL
whereas	NULL
the	NULL
CRE	NULL
and	NULL
the	NULL
NF-Y	NULL
sites	NULL
were	NULL
protected	NULL
whatever	NULL
the	NULL
time	NULL
point	NULL
,	NULL
or	NULL
the	NULL
mAbs	NULL
combination	NULL
selected	NULL
to	NULL
stimulate	NULL
T	NULL
lymphocytes	NULL
,	NULL
the	NULL
CCRE	NULL
motif	NULL
became	NULL
exposed	NULL
only	NULL
when	NULL
cells	NULL
were	NULL
costimulated	NULL
with	NULL
a	NULL
mitogenic	NULL
combination	NULL
of	NULL
CD2+	NULL
CD28	NULL
mAbs	NULL
at	NULL
times	NULL
when	NULL
proliferation	NULL
began	NULL
to	NULL
take	NULL
place	NULL
(	NULL
96	NULL
h	NULL
)	NULL
.	NULL

The	NULL
same	NULL
site	NULL
remained	NULL
protected	NULL
Cyclin	NULL
A	NULL
expression	NULL
in	NULL
human	NULL
primary	NULL
T	NULL
lymphocytes	NULL
A	NULL
Plet	NULL
et	NULL
al	NULL
in	NULL
quiescent	NULL
cells	NULL
or	NULL
in	NULL
cells	NULL
stimulated	NULL
with	NULL
anti	NULL
CD2	NULL
or	NULL
anti	NULL
CD28	NULL
mAb	NULL
alone	NULL
(	NULL
Figure	NULL
3a	NULL
,	NULL
right	NULL
panel	NULL
,	NULL
last	NULL
lane	NULL
)	NULL
.	NULL

This	NULL
is	NULL
illustrated	NULL
in	NULL
a	NULL
more	NULL
quantitative	NULL
way	NULL
in	NULL
Figure	NULL
3b	NULL
.	NULL

The	NULL
average	NULL
of	NULL
the	NULL
signals	NULL
corresponding	NULL
to	NULL
A	NULL
-	NULL
|-12	NULL
79	NULL
&	NULL
6A	NULL
s	NULL
p-	NULL
--	NULL
84	NULL
14.6	NULL
--	NULL
A	NULL
co	NULL
$	NULL
Tnz~	NULL
Rc	NULL
0	NULL
|	NULL
+1L2	NULL
35.5	NULL
8	NULL
I-35.8	NULL
&	NULL
28.7	NULL
--	NULL
-°	NULL
a	NULL
ao	NULL
pS	NULL
sho	NULL
t	NULL
FL2-A	NULL
20	NULL
A	NULL
53	NULL
t=	NULL
]	NULL
Fu	NULL
8	NULL
B	NULL
10-	NULL
<	NULL
4	NULL
0	NULL
wt	NULL
mCCRE	NULL
Figure	NULL
2	NULL
Presence	NULL
of	NULL
a	NULL
transcriptional	NULL
negative	NULL
regulatory	NULL
element	NULL
in	NULL
cyclin	NULL
A	NULL
promoter	NULL
revealed	NULL
by	NULL
transfection	NULL
into	NULL
an	NULL
IL-2-dependent	NULL
T	NULL
cell	NULL
line	NULL
.	NULL

(	NULL
a	NULL
)	NULL
FACS	NULL
analysis	NULL
performed	NULL
on	NULL
Kit225	NULL
cells	NULL
grown	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
fetal	NULL
calf	NULL
serum	NULL
either	NULL
alone	NULL
(	NULL
top	NULL
panel	NULL
)	NULL
or	NULL
supplemented	NULL
with	NULL
IL-2	NULL
(	NULL
lower	NULL
panel	NULL
)	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
methods	NULL
.	NULL

Numbers	NULL
refer	NULL
to	NULL
the	NULL
proportion	NULL
of	NULL
each	NULL
cell	NULL
subpopulation	NULL
in	NULL
the	NULL
various	NULL
phases	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

(	NULL
b	NULL
)	NULL
quiescent	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
pGL2-CycA	NULL
(	NULL
wt	NULL
)	NULL
or	NULL
pGL2-CycAm	NULL
(	NULL
mCCRE	NULL
)	NULL
containing	NULL
respectively	NULL
the	NULL
wild	NULL
type	NULL
and	NULL
the	NULL
mutated	NULL
promoters	NULL
.	NULL

Luciferase	NULL
activity	NULL
was	NULL
measured	NULL
72	NULL
h	NULL
later	NULL
,	NULL
either	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
IL-2	NULL
(	NULL
open	NULL
rectangles	NULL
)	NULL
,	NULL
or	NULL
after	NULL
24	NULL
h	NULL
of	NULL
treatment	NULL
with	NULL
IL-2	NULL
(	NULL
closed	NULL
rectangles	NULL
)	NULL
.	NULL

Results	NULL
,	NULL
corresponding	NULL
to	NULL
two	NULL
experiments	NULL
carried	NULL
out	NULL
in	NULL
triplicates	NULL
,	NULL
were	NULL
normalized	NULL
to	NULL
A-galactosidase	NULL
activity	NULL
expressed	NULL
from	NULL
a	NULL
cotrans-fected	NULL
pSV-lacZ	NULL
vector	NULL
as	NULL
described	NULL
(	NULL
Barlat	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Huet	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
2577	NULL
Cyclin	NULL
A	NULL
expression	NULL
in	NULL
human	NULL
primary	NULL
T	NULL
lymphocytes	NULL
A	NULL
Plet	NULL
et	NULL
al	NULL
2578	NULL
a	NULL
he	NULL
E	NULL
co	NULL
E	NULL
co	NULL
E	NULL
3	NULL
S	NULL
3	NULL
o	NULL
o	NULL
€	NULL
£	NULL
o	NULL
&	NULL
E	NULL
€	NULL
£	NULL
(	NULL
i	NULL
S	NULL
``	NULL
n	NULL
S	NULL
t	NULL
A	NULL
A	NULL
o	NULL
o	NULL
o	NULL
[	NULL
an	NULL
)	NULL
o	NULL
3	NULL
5	NULL
0	NULL
0	NULL
0	NULL
£	NULL
5	NULL
o	NULL
0	NULL
mrs	NULL
.	NULL

sus	NULL
,	NULL
~~	NULL
``	NULL
¥	NULL
=	NULL
-	NULL
>	NULL
``	NULL
*	NULL
-me	NULL
-	NULL
>	NULL
os	NULL
CRE	NULL
nly	NULL
k	NULL
y	NULL
&	NULL
#	NULL
%	NULL
h	NULL
,	NULL
%	NULL
a	NULL
connie	NULL
mun	NULL
...	NULL
,	NULL
ih	NULL
comum	NULL
mame	NULL
ugk	NULL
aa	NULL
.	NULL

*	NULL
mol	NULL
,	NULL
``	NULL
*	NULL
«	NULL
wes	NULL
«	NULL
th	NULL
-	NULL
,	NULL
``	NULL
tuu	NULL
@	NULL
®	NULL
Wins	NULL
C	NULL
-	NULL
mams	NULL
#	NULL
o	NULL
u	NULL
,	NULL
,	NULL
e	NULL
Soe	NULL
:	NULL
caup	NULL
o	NULL
-	NULL
spm	NULL
go-tk	NULL
«	NULL
Al	NULL
NFY	NULL
II	NULL
-	NULL
>	NULL
-	NULL
>	NULL
deo	NULL
m	NULL
-	NULL
>	NULL
cae	NULL
»	NULL
g	NULL
-	NULL
>	NULL
CCRE	NULL
a	NULL
a*	NULL
Gema	NULL
:	NULL
s	NULL
«	NULL
go-	NULL
4	NULL
24	NULL
h	NULL
96	NULL
h	NULL
b	NULL
1007	NULL
Average	NULL
DMS	NULL
sensitivity	NULL
o	NULL
5	NULL
tio	NULL
in	NULL
vitro	NULL
quiescent	NULL
CD2	NULL
CD2+CD28	NULL
Figure	NULL
3	NULL
Identification	NULL
of	NULL
in	NULL
vivo	NULL
protein	NULL
binding	NULL
sites	NULL
in	NULL
proliferating	NULL
versus	NULL
resting	NULL
cells	NULL
.	NULL

(	NULL
a	NULL
)	NULL
Primary	NULL
T	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
medium	NULL
alone	NULL
(	NULL
unstimulated	NULL
)	NULL
,	NULL
stimulated	NULL
with	NULL
only	NULL
one	NULL
monoclonal	NULL
antibody	NULL
(	NULL
CD2	NULL
,	NULL
CD28	NULL
)	NULL
or	NULL
stimulated	NULL
with	NULL
the	NULL
mitogenic	NULL
combination	NULL
of	NULL
both	NULL
of	NULL
them	NULL
(	NULL
CD2	NULL
+	NULL
CD28	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
treated	NULL
with	NULL
DMS	NULL
after	NULL
1	NULL
(	NULL
left	NULL
panel	NULL
)	NULL
or	NULL
4	NULL
days	NULL
(	NULL
right	NULL
panel	NULL
)	NULL
of	NULL
treatment	NULL
,	NULL
and	NULL
their	NULL
DNA	NULL
was	NULL
prepared	NULL
for	NULL
in	NULL
vivo	NULL
footprinting	NULL
as	NULL
described	NULL
.	NULL

Genomic	NULL
footprinting	NULL
was	NULL
run	NULL
with	NULL
the	NULL
control	NULL
DMS/piperidin-treated	NULL
naked	NULL
DNA	NULL
(	NULL
in	NULL
vitro	NULL
)	NULL
prepared	NULL
from	NULL
T	NULL
lymphocytes	NULL
of	NULL
the	NULL
same	NULL
donor	NULL
.	NULL

Arrows	NULL
,	NULL
protected	NULL
G	NULL
residues	NULL
.	NULL

Note	NULL
that	NULL
there	NULL
is	NULL
each	NULL
DMS-sensitive	NULL
bands	NULL
of	NULL
the	NULL
CCRE	NULL
and	NULL
the	NULL
CRE	NULL
have	NULL
been	NULL
plotted	NULL
after	NULL
normalization	NULL
relative	NULL
to	NULL
a	NULL
set	NULL
of	NULL
invariant	NULL
bands	NULL
.	NULL

Only	NULL
the	NULL
mitogenic	NULL
combination	NULL
of	NULL
mAbs	NULL
(	NULL
CD2+	NULL
CD28	NULL
)	NULL
gave	NULL
rise	NULL
to	NULL
a	NULL
complete	NULL
relief	NULL
of	NULL
the	NULL
footprint	NULL
present	NULL
on	NULL
the	NULL
CCRE	NULL
,	NULL
whereas	NULL
anti	NULL
CD2	NULL
alone	NULL
was	NULL
inefficient	NULL
.	NULL

The	NULL
invariant	NULL
footprint	NULL
on	NULL
the	NULL
CRE	NULL
is	NULL
provided	NULL
as	NULL
an	NULL
internal	NULL
control	NULL
.	NULL

Proteins	NULL
binding	NULL
in	NULL
vitro	NULL
to	NULL
the	NULL
CCRE	NULL
of	NULL
cyclin	NULL
A	NULL
promoter	NULL
are	NULL
present	NULL
only	NULL
in	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
quiescent	NULL
T	NULL
lymphocytes	NULL
Nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
quiescent	NULL
T	NULL
lymphocytes	NULL
were	NULL
reached	NULL
with	NULL
a	NULL
series	NULL
of	NULL
probes	NULL
spanning	NULL
nucleotides	NULL
-74	NULL
to	NULL
+34	NULL
relative	NULL
to	NULL
the	NULL
3	NULL
most	NULL
transcription	NULL
initiation	NULL
site	NULL
,	NULL
and	NULL
containing	NULL
individual	NULL
mutations	NULL
of	NULL
respectively	NULL
,	NULL
the	NULL
CRE	NULL
,	NULL
the	NULL
NF-Y	NULL
and	NULL
the	NULL
CCRE	NULL
.	NULL

Three	NULL
major	NULL
retarded	NULL
complexes	NULL
were	NULL
clearly	NULL
visible	NULL
(	NULL
Figure	NULL
Sa	NULL
)	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
CRE	NULL
abolished	NULL
the	NULL
formation	NULL
of	NULL
the	NULL
fast	NULL
migrating	NULL
compex	NULL
1	NULL
,	NULL
and	NULL
decreased	NULL
as	NULL
well	NULL
as	NULL
the	NULL
intensity	NULL
of	NULL
the	NULL
slower	NULL
migrating	NULL
complex	NULL
3	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
NF-Y	NULL
site	NULL
decreased	NULL
by	NULL
a	NULL
factor	NULL
of	NULL
three	NULL
the	NULL
intensity	NULL
of	NULL
band	NULL
2	NULL
,	NULL
probably	NULL
allowing	NULL
the	NULL
detection	NULL
of	NULL
another	NULL
band	NULL
migrating	NULL
at	NULL
the	NULL
same	NULL
position	NULL
as	NULL
band	NULL
2	NULL
.	NULL

A	NULL
slight	NULL
reinforcement	NULL
of	NULL
both	NULL
bands	NULL
1	NULL
and	NULL
3	NULL
was	NULL
also	NULL
observed	NULL
.	NULL

Finally	NULL
,	NULL
mutation	NULL
of	NULL
the	NULL
CCRE	NULL
did	NULL
not	NULL
unstim	NULL
ulated	NULL
CD2	NULL
+	NULL
CD28	NULL
in	NULL
vitro	NULL
24	NULL
h	NULL
48h	NULL
72h	NULL
-	NULL
96h	NULL
SRF	NULL
s	NULL
**	NULL
s	NULL
$	NULL
-=	NULL
-	NULL
S+	NULL
#	NULL
3	NULL
;	NULL
NF-xB	NULL
®	NULL
fnd	NULL
«	NULL
ame	NULL
@	NULL
@	NULL
62	NULL
2	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
Figure	NULL
4	NULL
-	NULL
DMS/LM-PCR	NULL
in	NULL
vivo	NULL
footprinting	NULL
of	NULL
the	NULL
NF-xB	NULL
and	NULL
the	NULL
SRF-binding	NULL
sites	NULL
in	NULL
the	NULL
human	NULL
IL-2R	NULL
«	NULL
gene	NULL
.	NULL

Lane	NULL
1	NULL
:	NULL
in	NULL
vitro	NULL
methylated	NULL
DNA	NULL
of	NULL
peripheral	NULL
blood	NULL
T	NULL
lymphocytes	NULL
;	NULL
lane	NULL
3-6	NULL
:	NULL
in	NULL
vivo	NULL
methylated	NULL
DNA	NULL
of	NULL
stimulated	NULL
T	NULL
cells	NULL
harvested	NULL
after	NULL
24	NULL
,	NULL
48	NULL
,	NULL
72	NULL
and	NULL
96	NULL
h	NULL
(	NULL
respectively	NULL
lanes	NULL
3	NULL
to	NULL
6	NULL
)	NULL
of	NULL
anti	NULL
CD2+CD28	NULL
treatment	NULL
.	NULL

Arrows	NULL
,	NULL
protected	NULL
G	NULL
residues	NULL
;	NULL
asterisks	NULL
,	NULL
hypersensitive	NULL
sites	NULL
Cyclin	NULL
A	NULL
expression	NULL
in	NULL
human	NULL
primary	NULL
T	NULL
lymphocytes	NULL
A	NULL
Plet	NULL
et	NULL
al	NULL
lead	NULL
to	NULL
an	NULL
apparent	NULL
variation	NULL
in	NULL
band	NULL
intensity	NULL
.	NULL

This	NULL
last	NULL
result	NULL
could	NULL
be	NULL
interpreted	NULL
by	NULL
the	NULL
masking	NULL
of	NULL
the	NULL
complex	NULL
formed	NULL
on	NULL
the	NULL
CCRE	NULL
by	NULL
that	NULL
formed	NULL
with	NULL
the	NULL
NF-Y	NULL
site	NULL
,	NULL
the	NULL
two	NULL
complexes	NULL
having	NULL
identical	NULL
mobilities	NULL
.	NULL

The	NULL
latter	NULL
possibility	NULL
was	NULL
suggested	NULL
in	NULL
some	NULL
experiments	NULL
where	NULL
the	NULL
resolution	NULL
was	NULL
high	NULL
enough	NULL
to	NULL
visualize	NULL
two	NULL
closely	NULL
migrating	NULL
bands	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

We	NULL
then	NULL
used	NULL
these	NULL
probes	NULL
with	NULL
extracts	NULL
prepared	NULL
from	NULL
T	NULL
lymphocytes	NULL
stimulated	NULL
by	NULL
various	NULL
combinations	NULL
of	NULL
mAbs	NULL
.	NULL

When	NULL
the	NULL
wild	NULL
type	NULL
probe	NULL
was	NULL
used	NULL
,	NULL
stimulation	NULL
with	NULL
anti	NULL
CD2+CD28	NULL
gave	NULL
rise	NULL
to	NULL
a	NULL
a	NULL
-74	NULL
+34	NULL
7	NULL
probes	NULL
-	NULL
A	NULL
ﬁ	NULL
3	NULL
-	NULL
»	NULL
s	NULL
:	NULL
-	NULL
LW	NULL
1	NULL
-+	NULL
‘	NULL
mh	NULL
probes	NULL
WT	NULL
CREm	NULL
NFYm	NULL
CCREm	NULL
stimulating	NULL
antibody	NULL
:	NULL
_	NULL
_	NULL
33	NULL
6	NULL
1	NULL
probes	NULL
WT	NULL
CD2+CD28	NULL
,	NULL
24	NULL
h	NULL
CD2+CD28	NULL
,	NULL
96	NULL
h	NULL
CD2+CD28	NULL
,	NULL
24	NULL
h	NULL
CD2+CD28	NULL
,	NULL
96	NULL
h	NULL
NFY¥m	NULL
Figure	NULL
5	NULL
Protein	NULL
complexes	NULL
formed	NULL
in	NULL
vitro	NULL
with	NULL
large	NULL
probes	NULL
covering	NULL
the	NULL
region	NULL
conserved	NULL
between	NULL
mouse	NULL
and	NULL
human	NULL
(	NULL
-74	NULL
,	NULL
+34	NULL
)	NULL
.	NULL

(	NULL
a	NULL
)	NULL
Gel	NULL
shifts	NULL
were	NULL
carried	NULL
out	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
resting	NULL
T	NULL
lymphocytes	NULL
and	NULL
either	NULL
with	NULL
a	NULL
wild	NULL
type	NULL
probe	NULL
(	NULL
WT	NULL
)	NULL
or	NULL
a	NULL
probe	NULL
bearing	NULL
a	NULL
mutated	NULL
site	NULL
at	NULL
the	NULL
various	NULL
indicated	NULL
positions	NULL
(	NULL
CREm	NULL
,	NULL
NFYm	NULL
,	NULL
CCREm	NULL
)	NULL
.	NULL

Only	NULL
retarded	NULL
bands	NULL
are	NULL
shown	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
either	NULL
unstimulated	NULL
T	NULL
cells	NULL
(	NULL
-	NULL
)	NULL
or	NULL
cells	NULL
stimulated	NULL
with	NULL
a	NULL
combination	NULL
of	NULL
anti	NULL
CD2	NULL
plus	NULL
anti	NULL
CD28	NULL
(	NULL
CD2+CD28	NULL
)	NULL
and	NULL
harvested	NULL
after	NULL
24	NULL
h	NULL
or	NULL
4	NULL
days	NULL
.	NULL

Gel	NULL
shifts	NULL
were	NULL
carried	NULL
out	NULL
with	NULL
either	NULL
wild	NULL
type	NULL
probe	NULL
(	NULL
left	NULL
panel	NULL
)	NULL
or	NULL
probe	NULL
bearing	NULL
a	NULL
mutated	NULL
NF-Y	NULL
site	NULL
(	NULL
right	NULL
panel	NULL
)	NULL
.	NULL

Gels	NULL
were	NULL
dried	NULL
and	NULL
quantified	NULL
using	NULL
a	NULL
phosphorimager	NULL
more	NULL
DNA	NULL
in	NULL
the	NULL
lane	NULL
CD2	NULL
for	NULL
the	NULL
sample	NULL
prepared	NULL
at	NULL
96	NULL
h	NULL
(	NULL
right	NULL
panel	NULL
)	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Quantitative	NULL
analysis	NULL
of	NULL
the	NULL
sensitivity	NULL
to	NULL
DMS	NULL
of	NULL
the	NULL
CRE	NULL
and	NULL
the	NULL
CCRE	NULL
.	NULL

The	NULL
signals	NULL
corresponding	NULL
to	NULL
the	NULL
various	NULL
G	NULL
residues	NULL
indicated	NULL
by	NULL
arrows	NULL
in	NULL
A	NULL
were	NULL
scanned	NULL
and	NULL
their	NULL
intensities	NULL
divided	NULL
by	NULL
that	NULL
of	NULL
the	NULL
corresponding	NULL
positions	NULL
of	NULL
the	NULL
in	NULL
vitro	NULL
samples	NULL
.	NULL

The	NULL
results	NULL
corresponding	NULL
to	NULL
96	NULL
h	NULL
of	NULL
stimulation	NULL
by	NULL
the	NULL
indicated	NULL
stimuli	NULL
were	NULL
normalized	NULL
to	NULL
the	NULL
intensities	NULL
of	NULL
the	NULL
invariant	NULL
bands	NULL
indicated	NULL
by	NULL
stars	NULL
,	NULL
and	NULL
plotted	NULL
as	NULL
averages	NULL
.	NULL

In	NULL
vitro	NULL
refers	NULL
to	NULL
naked	NULL
DNA	NULL
methylated	NULL
in	NULL
vitro	NULL
.	NULL

'Quiescent	NULL
'	NULL
,	NULL
'CD2	NULL
'	NULL
and	NULL
'CD2	NULL
+	NULL
CD28	NULL
'	NULL
refer	NULL
respectively	NULL
to	NULL
DNAs	NULL
methylated	NULL
in	NULL
vivo	NULL
when	NULL
cells	NULL
were	NULL
either	NULL
quiescent	NULL
,	NULL
stimulated	NULL
with	NULL
anti	NULL
CD2	NULL
,	NULL
or	NULL
stimulated	NULL
with	NULL
anti	NULL
CD2	NULL
+	NULL
anti	NULL
CD28	NULL
.	NULL

Closed	NULL
bars	NULL
:	NULL
CCRE	NULL
;	NULL
Open	NULL
bars	NULL
;	NULL
CRE	NULL
2579	NULL
Cyclin	NULL
A	NULL
expression	NULL
in	NULL
human	NULL
primary	NULL
T	NULL
lymphocytes	NULL
A	NULL
Plet	NULL
et	NULL
al	NULL
2580	NULL
progressive	NULL
loss	NULL
of	NULL
bands	NULL
1	NULL
and	NULL
3	NULL
,	NULL
whereas	NULL
band	NULL
2	NULL
persisted	NULL
,	NULL
suggesting	NULL
the	NULL
constitutive	NULL
binding	NULL
of	NULL
some	NULL
of	NULL
these	NULL
factors	NULL
(	NULL
Figure	NULL
5b	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
when	NULL
the	NULL
probe	NULL
mutated	NULL
on	NULL
the	NULL
NF-Y	NULL
site	NULL
was	NULL
used	NULL
,	NULL
a	NULL
progressive	NULL
loss	NULL
of	NULL
all	NULL
three	NULL
bands	NULL
was	NULL
observed	NULL
with	NULL
the	NULL
transient	NULL
appearance	NULL
of	NULL
a	NULL
fourth	NULL
type	NULL
of	NULL
complex	NULL
between	NULL
bands	NULL
2	NULL
and	NULL
3	NULL
.	NULL

These	NULL
observations	NULL
could	NULL
tentatively	NULL
be	NULL
explained	NULL
by	NULL
an	NULL
anchoring	NULL
role	NULL
for	NULL
NF-Y	NULL
,	NULL
which	NULL
could	NULL
stabilize	NULL
the	NULL
binding	NULL
of	NULL
factors	NULL
to	NULL
the	NULL
other	NULL
sites	NULL
nearby	NULL
.	NULL

Because	NULL
of	NULL
the	NULL
complexity	NULL
of	NULL
the	NULL
patterns	NULL
obtained	NULL
with	NULL
the	NULL
large	NULL
probes	NULL
,	NULL
we	NULL
next	NULL
switched	NULL
to	NULL
oligonucleotides	NULL
containing	NULL
individual	NULL
sites	NULL
(	NULL
Figure	NULL
6	NULL
)	NULL
.	NULL

The	NULL
NF-Y	NULL
oligonucleotide	NULL
showed	NULL
a	NULL
prominent	NULL
,	NULL
slowly	NULL
migrating	NULL
complex	NULL
,	NULL
together	NULL
with	NULL
a	NULL
set	NULL
of	NULL
fast	NULL
migrating	NULL
bands	NULL
.	NULL

The	NULL
former	NULL
corresponded	NULL
to	NULL
a	NULL
constitutive	NULL
and	NULL
specific	NULL
binding	NULL
of	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
whatever	NULL
the	NULL
origin	NULL
of	NULL
the	NULL
extract	NULL
and	NULL
was	NULL
therefore	NULL
used	NULL
as	NULL
an	NULL
internal	NULL
standard	NULL
of	NULL
gel	NULL
loading	NULL
.	NULL

The	NULL
faster	NULL
migrating	NULL
bands	NULL
were	NULL
not	NULL
considered	NULL
as	NULL
specific	NULL
as	NULL
they	NULL
were	NULL
equally	NULL
competed	NULL
by	NULL
both	NULL
a	NULL
wild	NULL
type	NULL
(	NULL
Figure	NULL
6	NULL
)	NULL
and	NULL
a	NULL
mutated	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
NF-Y	NULL
oligonucleotides	NULL
.	NULL

An	NULL
antibody	NULL
directed	NULL
at	NULL
the	NULL
B	NULL
subunit	NULL
of	NULL
NF-Y	NULL
displaced	NULL
quantitatively	NULL
the	NULL
retarded	NULL
band	NULL
into	NULL
a	NULL
slower	NULL
migrating	NULL
complex	NULL
.	NULL

A	NULL
C	NULL
C	NULL
C	NULL
C	NULL
<	NULL
to	NULL
©	NULL
<	NULL
to	NULL
o	NULL
N.	NULL
01	NULL
c	NULL
c	NULL
Q	NULL
!	NULL

-	NULL
0	NULL
)	NULL
-c	NULL
co	NULL
<	NULL
<	NULL
c	NULL
c	NULL
8	NULL
8	NULL
=	NULL
&	NULL
\	NULL
8	NULL
8	NULL
0	NULL
o	NULL
co	NULL
co	NULL
0	NULL
o	NULL
+o	NULL
+	NULL
ad	NULL
[	NULL
ad	NULL
+o	NULL
+	NULL
.	NULL

.	NULL

wow	NULL
o	NULL
o	NULL
--	NULL
a-	NULL
w	NULL
stimulating	NULL
o	NULL
A	NULL
O	NULL
O	NULL
8	NULL
8	NULL
antibodies	NULL
~-	NULL
?	NULL

V	NULL
competitor	NULL
-	NULL
-	NULL
-	NULL
-	NULL
+	NULL
Hoe	NULL
-	NULL
-o	NULL
-	NULL
-o	NULL
-o	NULL
+	NULL
-	NULL
_o	NULL
2	NULL
=_	NULL
|	NULL
wast	NULL
loud	NULL
tad	NULL
bad	NULL
inst	NULL
wat	NULL
Co	NULL
b=a	NULL
whale	NULL
.	NULL

lik	NULL
aand	NULL
thiis	NULL
haud	NULL
PBB	NULL
NFY	NULL
CCRE	NULL
u	NULL
.	NULL

<	NULL
©	NULL
|	NULL
m	NULL
=	NULL
#	NULL
i	NULL
5	NULL
8	NULL
antibodies	NULL
-	NULL
-	NULL
-	NULL
O	NULL
<	NULL
O	NULL
O	NULL
competitor	NULL
-	NULL
wt	NULL
mut	NULL
-	NULL
-	NULL
-	NULL
CRE	NULL
Figure	NULL
6	NULL
In	NULL
vitro	NULL
protein	NULL
binding	NULL
to	NULL
the	NULL
cyclin	NULL
A	NULL
NF-Y	NULL
,	NULL
CCRE	NULL
or	NULL
CRE	NULL
oligonucleotides	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
as	NULL
indicated	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Figure	NULL
5b	NULL
.	NULL

For	NULL
each	NULL
probe	NULL
,	NULL
a	NULL
competition	NULL
assay	NULL
was	NULL
performed	NULL
with	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
unlabeled	NULL
corresponding	NULL
oligonucleotide	NULL
(	NULL
competitor	NULL
)	NULL
added	NULL
in	NULL
the	NULL
reaction	NULL
mixture	NULL
.	NULL

wt	NULL
and	NULL
mut	NULL
refer	NULL
respectively	NULL
to	NULL
the	NULL
wild	NULL
type	NULL
and	NULL
mutated	NULL
version	NULL
of	NULL
the	NULL
oligonucleotide	NULL
.	NULL

When	NULL
indicated	NULL
,	NULL
extracts	NULL
were	NULL
incubated	NULL
with	NULL
antibodies	NULL
directed	NULL
respectively	NULL
against	NULL
the	NULL
Yb	NULL
subunit	NULL
of	NULL
NF-Y	NULL
(	NULL
«	NULL
Yb	NULL
)	NULL
,	NULL
the	NULL
CREB/ATF	NULL
family	NULL
,	NULL
ATF-1	NULL
,	NULL
CREB	NULL
or	NULL
CREM	NULL
,	NULL
1	NULL
h	NULL
prior	NULL
to	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
probe	NULL
similar	NULL
supershift	NULL
was	NULL
introduced	NULL
by	NULL
an	NULL
antibody	NULL
directed	NULL
at	NULL
the	NULL
A	NULL
subunit	NULL
of	NULL
the	NULL
same	NULL
factor	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
thus	NULL
identifying	NULL
this	NULL
sequence	NULL
as	NULL
an	NULL
in	NULL
vitro	NULL
high	NULL
affinity	NULL
site	NULL
for	NULL
NF-Y	NULL
.	NULL

Similarly	NULL
,	NULL
analysis	NULL
on	NULL
proteins	NULL
binding	NULL
to	NULL
the	NULL
CRE	NULL
probe	NULL
revealed	NULL
an	NULL
invariant	NULL
binding	NULL
whether	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
quiescent	NULL
or	NULL
stimulated	NULL
cells	NULL
.	NULL

We	NULL
thus	NULL
show	NULL
in	NULL
Figure	NULL
6	NULL
only	NULL
results	NULL
obtained	NULL
with	NULL
extracts	NULL
from	NULL
quiescent	NULL
cells	NULL
.	NULL

The	NULL
more	NULL
prominent	NULL
specific	NULL
retarded	NULL
complexes	NULL
were	NULL
supershifted	NULL
as	NULL
expected	NULL
by	NULL
broad	NULL
specificity	NULL
antibodies	NULL
reacting	NULL
with	NULL
all	NULL
members	NULL
of	NULL
the	NULL
CREB/ATF	NULL
families	NULL
.	NULL

When	NULL
monoclonal	NULL
antibodies	NULL
directed	NULL
at	NULL
specific	NULL
members	NULL
of	NULL
these	NULL
families	NULL
were	NULL
used	NULL
,	NULL
only	NULL
anti-ATF-1	NULL
gave	NULL
rise	NULL
to	NULL
a	NULL
strong	NULL
supershift	NULL
.	NULL

A	NULL
specific	NULL
complex	NULL
was	NULL
also	NULL
formed	NULL
with	NULL
the	NULL
CCRE	NULL
probe	NULL
and	NULL
extracts	NULL
from	NULL
quiescent	NULL
as	NULL
well	NULL
as	NULL
for	NULL
24	NULL
h	NULL
stimulated	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
extracts	NULL
from	NULL
cells	NULL
stimulated	NULL
for	NULL
longer	NULL
times	NULL
failed	NULL
to	NULL
form	NULL
stable	NULL
complexes	NULL
in	NULL
vitro	NULL
.	NULL

As	NULL
the	NULL
CCRE	NULL
core	NULL
sequence	NULL
is	NULL
GC-rich	NULL
,	NULL
we	NULL
tried	NULL
competitions	NULL
with	NULL
unlabelled	NULL
nucleotides	NULL
corresponding	NULL
respectively	NULL
to	NULL
SP1	NULL
and	NULL
E2F	NULL
consensus	NULL
sites	NULL
without	NULL
any	NULL
success	NULL
.	NULL

At	NULL
the	NULL
moment	NULL
,	NULL
the	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
binding	NULL
to	NULL
the	NULL
cyclin	NULL
A	NULL
CCRE	NULL
is	NULL
still	NULL
unknown	NULL
and	NULL
its	NULL
characterization	NULL
will	NULL
await	NULL
further	NULL
work	NULL
.	NULL

Discussion	NULL
Numerous	NULL
studies	NULL
conducted	NULL
in	NULL
immortalized	NULL
or	NULL
transformed	NULL
cell	NULL
lines	NULL
have	NULL
shown	NULL
that	NULL
cyclin	NULL
A	NULL
mRNA	NULL
accumulation	NULL
is	NULL
cell	NULL
cycle	NULL
regulated	NULL
by	NULL
a	NULL
transcriptional	NULL
activation	NULL
of	NULL
its	NULL
gene	NULL
in	NULL
the	NULL
late	NULL
G	NULL
;	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
division	NULL
cycle	NULL
(	NULL
Barlat	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
Henglein	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Schulze	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Zwicker	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Huet	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

We	NULL
have	NULL
therefore	NULL
undertaken	NULL
the	NULL
analysis	NULL
of	NULL
sequences	NULL
and	NULL
factors	NULL
involved	NULL
in	NULL
the	NULL
control	NULL
of	NULL
the	NULL
expression	NULL
of	NULL
this	NULL
gene	NULL
under	NULL
conditions	NULL
close	NULL
to	NULL
physiological	NULL
ones	NULL
.	NULL

To	NULL
this	NULL
aim	NULL
,	NULL
we	NULL
have	NULL
analysed	NULL
the	NULL
in	NULL
vivo	NULL
chromatin	NULL
structure	NULL
at	NULL
the	NULL
cyclin	NULL
A	NULL
locus	NULL
in	NULL
primary	NULL
T	NULL
human	NULL
lymphocytes	NULL
.	NULL

Comparison	NULL
of	NULL
the	NULL
sequences	NULL
of	NULL
the	NULL
human	NULL
and	NULL
mouse	NULL
promoters	NULL
had	NULL
revealed	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
region	NULL
of	NULL
striking	NULL
homology	NULL
containing	NULL
a	NULL
cAMP	NULL
responsive	NULL
element	NULL
(	NULL
CRE	NULL
)	NULL
,	NULL
a	NULL
NF-Y	NULL
binding	NULL
site	NULL
,	NULL
and	NULL
a	NULL
GC-rich	NULL
motif	NULL
(	NULL
Zwicker	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Schulze	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Huet	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

Our	NULL
previous	NULL
work	NULL
on	NULL
cyclin	NULL
A	NULL
down	NULL
regulation	NULL
of	NULL
TGF-B	NULL
had	NULL
pointed	NULL
to	NULL
the	NULL
CRE	NULL
as	NULL
an	NULL
important	NULL
mediator	NULL
of	NULL
the	NULL
inhibitory	NULL
effect	NULL
of	NULL
the	NULL
cytokine	NULL
(	NULL
Barlat	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
,	NULL
1995	NULL
)	NULL
.	NULL

However	NULL
,	NULL
a	NULL
promoter	NULL
,	NULL
mutated	NULL
on	NULL
the	NULL
CRE	NULL
,	NULL
was	NULL
still	NULL
able	NULL
to	NULL
respond	NULL
to	NULL
serum	NULL
stimulation	NULL
albeit	NULL
at	NULL
a	NULL
lower	NULL
efficiency	NULL
.	NULL

DMS	NULL
footprinting	NULL
of	NULL
proteins	NULL
binding	NULL
in	NULL
vivo	NULL
to	NULL
this	NULL
locus	NULL
in	NULL
T	NULL
lymphocytes	NULL
stimulated	NULL
with	NULL
appropriate	NULL
combinations	NULL
of	NULL
mAbs	NULL
directed	NULL
at	NULL
cell	NULL
surface	NULL
molecules	NULL
,	NULL
revealed	NULL
the	NULL
presence	NULL
of	NULL
several	NULL
protected	NULL
regions	NULL
near	NULL
the	NULL
major	NULL
transcription	NULL
initiation	NULL
sites	NULL
.	NULL

Whereas	NULL
the	NULL
CRE	NULL
and	NULL
the	NULL
NF-Y	NULL
sites	NULL
were	NULL
occupied	NULL
whichever	NULL
combination	NULL
of	NULL
mAbs	NULL
selected	NULL
,	NULL
the	NULL
occupancy	NULL
of	NULL
the	NULL
GC-rich	NULL
site	NULL
was	NULL
specifically	NULL
observed	NULL
in	NULL
quiescent	NULL
cells	NULL
or	NULL
in	NULL
cells	NULL
stimulated	NULL
with	NULL
non-mitogenic	NULL
mAbs	NULL
.	NULL

Conversely	NULL
,	NULL
when	NULL
lymphocytes	NULL
were	NULL
exposed	NULL
to	NULL
a	NULL
mitogenic	NULL
anti	NULL
CD2	NULL
costimulation	NULL
,	NULL
the	NULL
footprint	NULL
present	NULL
on	NULL
the	NULL
CCRE	NULL
was	NULL
released	NULL
at	NULL
late	NULL
times	NULL
of	NULL
stimulation	NULL
when	NULL
cells	NULL
had	NULL
entered	NULL
a	NULL
proliferative	NULL
programme	NULL
.	NULL

Occupancy	NULL
of	NULL
the	NULL
CCRE	NULL
was	NULL
thus	NULL
observed	NULL
only	NULL
when	NULL
cyclin	NULL
A	NULL
gene	NULL
was	NULL
transcriptionally	NULL
silent	NULL
.	NULL

This	NULL
suggested	NULL
the	NULL
possibility	NULL
of	NULL
the	NULL
binding	NULL
of	NULL
a	NULL
transcriptional	NULL
inhibitor	NULL
to	NULL
this	NULL
region	NULL
.	NULL

This	NULL
prompted	NULL
us	NULL
to	NULL
look	NULL
for	NULL
proteins	NULL
binding	NULL
to	NULL
a	NULL
CCRE	NULL
probe	NULL
in	NULL
vitro	NULL
in	NULL
a	NULL
standard	NULL
gel	NULL
shift	NULL
assay	NULL
.	NULL

A	NULL
specific	NULL
binding	NULL
was	NULL
observed	NULL
with	NULL
extracts	NULL
prepared	NULL
from	NULL
quiescent	NULL
cells	NULL
and	NULL
not	NULL
from	NULL
cells	NULL
stimulated	NULL
with	NULL
anti	NULL
CD2+	NULL
CD28	NULL
at	NULL
times	NULL
where	NULL
cells	NULL
were	NULL
actively	NULL
growing	NULL
.	NULL

As	NULL
a	NULL
control	NULL
,	NULL
the	NULL
NF-Y	NULL
probe	NULL
showed	NULL
a	NULL
constitutive	NULL
binding	NULL
.	NULL

A	NULL
recent	NULL
report	NULL
(	NULL
Zwicker	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
evidenced	NULL
the	NULL
cell	NULL
cycle	NULL
regulation	NULL
of	NULL
the	NULL
B-myb	NULL
E2F	NULL
site	NULL
occupation	NULL
in	NULL
vivo	NULL
in	NULL
serum-stimulated	NULL
NIH3T3	NULL
cells	NULL
.	NULL

Despite	NULL
the	NULL
weak	NULL
similitudes	NULL
between	NULL
the	NULL
human	NULL
cyclin	NULL
A	NULL
CCRE	NULL
and	NULL
the	NULL
murine	NULL
B-myb	NULL
E2F	NULL
sites	NULL
(	NULL
respectively	NULL
GTCGCGGG	NULL
and	NULL
CTTGGCGG	NULL
)	NULL
,	NULL
both	NULL
sites	NULL
present	NULL
a	NULL
loss	NULL
of	NULL
protection	NULL
in	NULL
vivo	NULL
that	NULL
coincided	NULL
with	NULL
the	NULL
onset	NULL
of	NULL
transcription	NULL
of	NULL
the	NULL
respective	NULL
genes	NULL
.	NULL

Based	NULL
upon	NULL
similar	NULL
patterns	NULL
of	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
methylated	NULL
guanine	NULL
protection	NULL
,	NULL
the	NULL
authors	NULL
proposed	NULL
that	NULL
the	NULL
protein	NULL
complex	NULL
interacting	NULL
in	NULL
vivo	NULL
was	NULL
indeed	NULL
E2F	NULL
.	NULL

However	NULL
,	NULL
no	NULL
electromobility-shift	NULL
assays	NULL
performed	NULL
in	NULL
parallel	NULL
with	NULL
nuclear	NULL
extract	NULL
from	NULL
cell-cycle	NULL
synchronized	NULL
NIH3T3	NULL
cells	NULL
were	NULL
presented	NULL
.	NULL

Our	NULL
data	NULL
do	NULL
not	NULL
allow	NULL
us	NULL
to	NULL
conclude	NULL
whether	NULL
the	NULL
CCRE	NULL
repressor	NULL
is	NULL
one	NULL
of	NULL
the	NULL
known	NULL
E2F	NULL
complexes	NULL
.	NULL

Further	NULL
experiments	NULL
are	NULL
required	NULL
to	NULL
elucidate	NULL
whether	NULL
the	NULL
factors	NULL
at	NULL
play	NULL
in	NULL
the	NULL
two	NULL
experimental	NULL
models	NULL
are	NULL
either	NULL
identical	NULL
or	NULL
only	NULL
similar	NULL
in	NULL
their	NULL
consequence	NULL
of	NULL
in	NULL
vivo	NULL
occupancy	NULL
.	NULL

While	NULL
this	NULL
work	NULL
was	NULL
completed	NULL
,	NULL
two	NULL
reports	NULL
(	NULL
Schulze	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Zwicker	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
pointed	NULL
to	NULL
the	NULL
CCRE	NULL
as	NULL
an	NULL
important	NULL
element	NULL
in	NULL
controlling	NULL
the	NULL
cell	NULL
cycle	NULL
behaviour	NULL
of	NULL
human	NULL
cyclin	NULL
A	NULL
promoter	NULL
,	NULL
but	NULL
diverged	NULL
on	NULL
the	NULL
nature	NULL
of	NULL
the	NULL
protein	NULL
(	NULL
s	NULL
)	NULL
binding	NULL
in	NULL
vitro	NULL
to	NULL
this	NULL
sequence	NULL
.	NULL

The	NULL
former	NULL
group	NULL
(	NULL
Schulze	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
proposed	NULL
that	NULL
members	NULL
of	NULL
the	NULL
E2F/DP	NULL
family	NULL
together	NULL
with	NULL
pockets	NULL
proteins	NULL
were	NULL
binding	NULL
to	NULL
the	NULL
CCRE	NULL
,	NULL
whereas	NULL
the	NULL
latter	NULL
group	NULL
(	NULL
Zwicker	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
did	NULL
not	NULL
succeed	NULL
in	NULL
characterizing	NULL
proteins	NULL
interacting	NULL
with	NULL
this	NULL
sequence	NULL
,	NULL
and	NULL
even	NULL
alluded	NULL
to	NULL
the	NULL
fact	NULL
that	NULL
recombinant	NULL
E2F-1	NULL
was	NULL
not	NULL
binding	NULL
in	NULL
vitro	NULL
to	NULL
the	NULL
CCRE	NULL
.	NULL

In	NULL
a	NULL
previous	NULL
work	NULL
(	NULL
Huet	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
,	NULL
we	NULL
had	NULL
shown	NULL
that	NULL
mutation	NULL
of	NULL
the	NULL
GC-rich	NULL
sequence	NULL
led	NULL
to	NULL
a	NULL
10-fold	NULL
increase	NULL
in	NULL
the	NULL
reporter	NULL
activity	NULL
and	NULL
almost	NULL
totally	NULL
impaired	NULL
its	NULL
cell	NULL
cycle-dependent	NULL
activation	NULL
,	NULL
when	NULL
assayed	NULL
by	NULL
transient	NULL
transfection	NULL
,	NULL
thus	NULL
confirming	NULL
its	NULL
negative	NULL
regulatory	NULL
role	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
CCRE	NULL
sequence	NULL
was	NULL
not	NULL
sufficient	NULL
to	NULL
endow	NULL
an	NULL
enhancer-less	NULL
promoter	NULL
with	NULL
a	NULL
cell	NULL
cycle-responsiveness	NULL
.	NULL

This	NULL
result	NULL
thus	NULL
suggests	NULL
a	NULL
cooperation	NULL
between	NULL
the	NULL
CCRE	NULL
and	NULL
other	NULL
sequences	NULL
,	NULL
either	NULL
promoter-proximal	NULL
such	NULL
as	NULL
the	NULL
CRE	NULL
or	NULL
the	NULL
NF-Y	NULL
,	NULL
or	NULL
more	NULL
distal	NULL
and	NULL
which	NULL
remain	NULL
to	NULL
be	NULL
defined	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
a	NULL
constitutive	NULL
in	NULL
vivo	NULL
footprint	NULL
on	NULL
both	NULL
the	NULL
CRE	NULL
and	NULL
the	NULL
NF-Y	NULL
sites	NULL
nearby	NULL
points	NULL
to	NULL
their	NULL
possible	NULL
involvement	NULL
in	NULL
modulating	NULL
the	NULL
CCRE	NULL
activity	NULL
.	NULL

The	NULL
apparent	NULL
discrepancy	NULL
between	NULL
the	NULL
constitutive	NULL
occupancy	NULL
of	NULL
the	NULL
CRE	NULL
and	NULL
the	NULL
absence	NULL
of	NULL
complex	NULL
in	NULL
gel	NULL
shift	NULL
performed	NULL
with	NULL
the	NULL
mutated	NULL
large	NULL
probe	NULL
and	NULL
extracts	NULL
from	NULL
mitogenically	NULL
stimulated	NULL
cells	NULL
,	NULL
again	NULL
points	NULL
to	NULL
a	NULL
cooperation	NULL
between	NULL
the	NULL
binding	NULL
sites	NULL
in	NULL
this	NULL
region	NULL
.	NULL

They	NULL
are	NULL
several	NULL
possible	NULL
mechanisms	NULL
,	NULL
which	NULL
are	NULL
not	NULL
mutually	NULL
exclusive	NULL
.	NULL

First	NULL
of	NULL
all	NULL
,	NULL
the	NULL
structure	NULL
of	NULL
the	NULL
entire	NULL
region	NULL
,	NULL
such	NULL
as	NULL
its	NULL
curvature	NULL
,	NULL
could	NULL
be	NULL
modified	NULL
by	NULL
the	NULL
binding	NULL
of	NULL
the	NULL
different	NULL
factors	NULL
.	NULL

An	NULL
effect	NULL
visible	NULL
only	NULL
with	NULL
large	NULL
probes	NULL
spanning	NULL
the	NULL
entire	NULL
region	NULL
.	NULL

The	NULL
same	NULL
factors	NULL
could	NULL
also	NULL
transiently	NULL
attract	NULL
an	NULL
auxiliary	NULL
protein	NULL
not	NULL
Cyclin	NULL
A	NULL
expression	NULL
in	NULL
human	NULL
primary	NULL
T	NULL
lymphocytes	NULL
A	NULL
Plet	NULL
et	NULL
al	NULL
necessarily	NULL
directly	NULL
contacting	NULL
DNA	NULL
,	NULL
which	NULL
could	NULL
explain	NULL
the	NULL
transient	NULL
appearance	NULL
of	NULL
band	NULL
4	NULL
.	NULL

Finally	NULL
,	NULL
we	NULL
propose	NULL
that	NULL
the	NULL
NF-Y	NULL
factor	NULL
could	NULL
organize	NULL
the	NULL
binding	NULL
of	NULL
the	NULL
nearby	NULL
factors	NULL
.	NULL

Such	NULL
a	NULL
situation	NULL
is	NULL
not	NULL
unprecedented	NULL
and	NULL
previous	NULL
report	NULL
have	NULL
pointed	NULL
to	NULL
the	NULL
possibility	NULL
that	NULL
NF-Y	NULL
might	NULL
facilitate	NULL
in	NULL
vivo	NULL
recruitment	NULL
of	NULL
upstream	NULL
DNA	NULL
binding	NULL
transcription	NULL
factors	NULL
(	NULL
Wright	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Coustry	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

The	NULL
resolution	NULL
of	NULL
this	NULL
problem	NULL
will	NULL
await	NULL
the	NULL
purification	NULL
of	NULL
the	NULL
factor	NULL
binding	NULL
to	NULL
the	NULL
CCRE	NULL
and	NULL
the	NULL
establisment	NULL
of	NULL
an	NULL
in	NULL
vitro	NULL
assay	NULL
to	NULL
study	NULL
these	NULL
multiple	NULL
interactions	NULL
.	NULL

Materials	NULL
and	NULL
methods	NULL
Cell	NULL
culture	NULL
and	NULL
transfection	NULL
Peripheral	NULL
lymphocytes	NULL
were	NULL
isolated	NULL
from	NULL
voluntary	NULL
,	NULL
healthy	NULL
donors	NULL
and	NULL
purified	NULL
as	NULL
described	NULL
(	NULL
Cerdan	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

Purity	NULL
of	NULL
T	NULL
cell	NULL
preparations	NULL
(	NULL
>	NULL
99	NULL
%	NULL
)	NULL
was	NULL
checked	NULL
by	NULL
immunofluorescence	NULL
labelling	NULL
with	NULL
various	NULL
mAbs	NULL
specific	NULL
respectively	NULL
for	NULL
monocytes	NULL
,	NULL
B	NULL
and	NULL
NK	NULL
cells	NULL
.	NULL

Contamination	NULL
by	NULL
monocytes	NULL
was	NULL
also	NULL
checked	NULL
by	NULL
the	NULL
absence	NULL
of	NULL
proliferation	NULL
upon	NULL
optimal	NULL
stimulation	NULL
with	NULL
PHA	NULL
.	NULL

Cells	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
FCS	NULL
)	NULL
,	NULL
and	NULL
activated	NULL
with	NULL
the	NULL
indicated	NULL
antibodies	NULL
.	NULL

Kit225	NULL
,	NULL
an	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
-dependent	NULL
human	NULL
T	NULL
cell	NULL
line	NULL
(	NULL
Hori	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
,	NULL
was	NULL
maintained	NULL
in	NULL
RPMI	NULL
1650	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
2	NULL
mM	NULL
L-glutamine	NULL
and	NULL
1	NULL
nM	NULL
recombinant	NULL
IL-2	NULL
(	NULL
Eurocetus	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
growth-arrested	NULL
by	NULL
culturing	NULL
them	NULL
for	NULL
48	NULL
h	NULL
in	NULL
IL-2-free	NULL
medium	NULL
.	NULL

When	NULL
needed	NULL
,	NULL
cells	NULL
were	NULL
sorted	NULL
according	NULL
to	NULL
their	NULL
DNA	NULL
content	NULL
with	NULL
a	NULL
FACScan	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
after	NULL
labelling	NULL
with	NULL
propidium	NULL
iodide	NULL
as	NULL
described	NULL
(	NULL
Huet	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

After	NULL
a	NULL
24	NULL
h	NULL
period	NULL
of	NULL
growth	NULL
in	NULL
low	NULL
IL-2	NULL
(	NULL
50	NULL
U/ml	NULL
)	NULL
,	NULL
2	NULL
x	NULL
10°	NULL
cells	NULL
were	NULL
washed	NULL
three	NULL
times	NULL
with	NULL
PBS	NULL
,	NULL
concentration	NULL
to	NULL
10°	NULL
cells/ml	NULL
in	NULL
serum	NULL
and	NULL
IL-2-free	NULL
medium	NULL
,	NULL
and	NULL
transfected	NULL
by	NULL
exposition	NULL
for	NULL
5	NULL
h	NULL
to	NULL
2	NULL
ug	NULL
DNA	NULL
and	NULL
8	NULL
ug	NULL
DMIERC	NULL
(	NULL
GIBCO	NULL
)	NULL
.	NULL

Fifteen	NULL
percent	NULL
fetal	NULL
calf	NULL
serum	NULL
was	NULL
then	NULL
added	NULL
,	NULL
and	NULL
cells	NULL
grown	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
IL-2	NULL
for	NULL
an	NULL
additional	NULL
48	NULL
h.	NULL
Luciferase	NULL
activity	NULL
was	NULL
monitored	NULL
24	NULL
h	NULL
later	NULL
,	NULL
after	NULL
addition	NULL
of	NULL
IL-2	NULL
to	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
360	NULL
U/ml	NULL
.	NULL

In	NULL
vivo	NULL
genomic	NULL
footprint	NULL
analysis	NULL
10	NULL
'	NULL
cells	NULL
were	NULL
concentrated	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
RPMI	NULL
containing	NULL
10	NULL
%	NULL
FCS	NULL
and	NULL
20	NULL
mm	NULL
HEPES	NULL
(	NULL
pH	NULL
7.3	NULL
)	NULL
,	NULL
then	NULL
exposed	NULL
for	NULL
1	NULL
min	NULL
to	NULL
5	NULL
ul/ml	NULL
dimethylsuiphate	NULL
and	NULL
the	NULL
reaction	NULL
quenched	NULL
with	NULL
2	NULL
%	NULL
-	NULL
B-mercaptocethanol	NULL
,	NULL
followed	NULL
by	NULL
washing	NULL
in	NULL
cold	NULL
PBS	NULL
.	NULL

After	NULL
extraction	NULL
of	NULL
genomic	NULL
DNA	NULL
and	NULL
Piperidine	NULL
cleavage	NULL
of	NULL
methylated	NULL
Guanines	NULL
,	NULL
methyla-tion	NULL
interference	NULL
was	NULL
monitored	NULL
using	NULL
a	NULL
ligation	NULL
mediated	NULL
PCR	NULL
(	NULL
LM-PCR	NULL
)	NULL
as	NULL
described	NULL
(	NULL
Garrity	NULL
and	NULL
Wold	NULL
,	NULL
1992	NULL
;	NULL
Barlat	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

The	NULL
following	NULL
oligonucleotides	NULL
were	NULL
used	NULL
:	NULL
for	NULL
the	NULL
cyclin	NULL
A	NULL
locus	NULL
:	NULL
-GCGGGAGGAGCGTAGAGCCC	NULL
-AGCCCAGGAGCCGCGAGCTG	NULL
-CAGGAGCCGCGAGCTGCGCG	NULL
for	NULL
the	NULL
IL-2Ra	NULL
locus	NULL
:	NULL
-TGACTCCTGAGGACGTTA	NULL
-GGGGAGGACTCAGCTTATGAAGTGC	NULL
-CAGCTTATGAAGTGCTGGGTGAGACCACT	NULL
The	NULL
last	NULL
oligonucleotides	NULL
of	NULL
each	NULL
set	NULL
were	NULL
labelled	NULL
with	NULL
T4	NULL
polynucleotide	NULL
kinase	NULL
and	NULL
[	NULL
y	NULL
``	NULL
PJATP	NULL
,	NULL
and	NULL
radioactive	NULL
,	NULL
elongated	NULL
DNA	NULL
was	NULL
fractionated	NULL
on	NULL
a	NULL
6	NULL
%	NULL
polyacrylamide	NULL
sequencing	NULL
gel	NULL
.	NULL

2581	NULL
Cyclin	NULL
A	NULL
expression	NULL
in	NULL
human	NULL
primary	NULL
T	NULL
lymphocytes	NULL
A	NULL
Plet	NULL
et	NULL
al	NULL
2582	NULL
Gel	NULL
mobility	NULL
shifts	NULL
The	NULL
large	NULL
probes	NULL
covering	NULL
the	NULL
region	NULL
conserved	NULL
between	NULL
mouse	NULL
and	NULL
human	NULL
(	NULL
-74	NULL
,	NULL
+34	NULL
)	NULL
,	NULL
were	NULL
synthesized	NULL
by	NULL
radioactive	NULL
PCR	NULL
amplification	NULL
using	NULL
as	NULL
starting	NULL
material	NULL
the	NULL
plasmids	NULL
containing	NULL
the	NULL
various	NULL
indicated	NULL
mutations	NULL
.	NULL

For	NULL
each	NULL
individual	NULL
site	NULL
,	NULL
the	NULL
following	NULL
double	NULL
stranded	NULL
oligonucleotide	NULL
corresponding	NULL
to	NULL
respectively	NULL
,	NULL
the	NULL
cyclin	NULL
A	NULL
CRE	NULL
,	NULL
the	NULL
NF-Y	NULL
and	NULL
the	NULL
CCRE	NULL
sites	NULL
were	NULL
used	NULL
:	NULL
CRE	NULL
:	NULL
NF-Y	NULL
:	NULL
5'-GAGCGCTTTCATTGGTCCATTT	NULL
CCRE	NULL
:	NULL
5'-GGGATTTCAATAGTCGCGGGCTACTTGAA	NULL
When	NULL
indicated	NULL
,	NULL
the	NULL
following	NULL
mutated	NULL
oligonucleotides	NULL
were	NULL
also	NULL
used	NULL
:	NULL
mCRE	NULL
:	NULL
5'-GGGTCGCCTTCAACGACCTCGAGGCCGCGA	NULL
mNF-Y	NULL
:	NULL
5'-GAGCGCTTGAATTCGTCCATTT	NULL
mCCRE	NULL
:	NULL
5'-GGGATTTCAATAGTCGAATTCTACTTGAA	NULL
The	NULL
annealed	NULL
oligonucleotides	NULL
described	NULL
above	NULL
,	NULL
were	NULL
either	NULL
end-labelled	NULL
with	NULL
T4	NULL
polynucleotide	NULL
kinase	NULL
and	NULL
[	NULL
yPJATP	NULL
(	NULL
3000	NULL
Ci/mmole	NULL
,	NULL
Amersham	NULL
)	NULL
,	NULL
or	NULL
labelled	NULL
by	NULL
filling	NULL
in	NULL
of	NULL
the	NULL
recessive	NULL
ends	NULL
with	NULL
Klenow	NULL
fragment	NULL
of	NULL
DNA	NULL
polymerase	NULL
I	NULL
and	NULL
[	NULL
«	NULL
``	NULL
P	NULL
]	NULL
JdCTP	NULL
(	NULL
3000	NULL
Ci/mmole	NULL
,	NULL
Amersham	NULL
)	NULL
.	NULL

For	NULL
nuclear	NULL
extracts	NULL
,	NULL
T	NULL
cells	NULL
were	NULL
washed	NULL
in	NULL
cold	NULL
Tris-buffered	NULL
saline	NULL
then	NULL
resuspended	NULL
in	NULL
0.4	NULL
ml	NULL
of	NULL
10	NULL
mm	NULL
HEPES	NULL
(	NULL
pH	NULL
7.8	NULL
)	NULL
,	NULL
10	NULL
mm	NULL
KCl	NULL
,	NULL
2	NULL
mm	NULL
MgCl	NULL
,	NULL
,	NULL
1	NULL
mm	NULL
dithiothreitol	NULL
,	NULL
0.1	NULL
mm	NULL
EDTA	NULL
,	NULL
0.1	NULL
mM	NULL
phenylmethylsuiphonyl	NULL
fluoride	NULL
,	NULL
0.3	NULL
mg/ml	NULL
leupeptine	NULL
,	NULL
for	NULL
15	NULL
min	NULL
on	NULL
ice	NULL
.	NULL

Twenty-five	NULL
ul	NULL
of	NULL
10	NULL
%	NULL
Nonidet-P40	NULL
was	NULL
then	NULL
added	NULL
,	NULL
and	NULL
after	NULL
a	NULL
15	NULL
s	NULL
vigorous	NULL
agitation	NULL
,	NULL
cells	NULL
were	NULL
spun	NULL
for	NULL
15s	NULL
at	NULL
13	NULL
000	NULL
r.p.m	NULL
.	NULL

(	NULL
Sorval	NULL
minicentrifuge	NULL
)	NULL
.	NULL

Nuclei	NULL
were	NULL
resuspended	NULL
in	NULL
50	NULL
ul	NULL
50	NULL
mM	NULL
HEPES	NULL
(	NULL
pH	NULL
7.8	NULL
)	NULL
,	NULL
50	NULL
mM	NULL
KCI	NULL
,	NULL
300	NULL
mm	NULL
NaCl	NULL
,	NULL
0.1	NULL
mm	NULL
EDTA	NULL
,	NULL
1	NULL
mm	NULL
dithiothreitol	NULL
,	NULL
0.1	NULL
mM	NULL
phenylmethylsulphonyl	NULL
fluoride	NULL
,	NULL
10	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
glycerol	NULL
for	NULL
20	NULL
min	NULL
and	NULL
then	NULL
centrifuged	NULL
for	NULL
5	NULL
min	NULL
at	NULL
13	NULL
000	NULL
r.p.m	NULL
.	NULL

The	NULL
cleared	NULL
supernatants	NULL
were	NULL
stored	NULL
at	NULL
-80°C	NULL
after	NULL
estimation	NULL
of	NULL
the	NULL
protein	NULL
concentration	NULL
according	NULL
to	NULL
Bradford	NULL
(	NULL
Bio-Rad	NULL
)	NULL
.	NULL

Two	NULL
ug	NULL
of	NULL
nuclear	NULL
extracts	NULL
were	NULL
used	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
either	NULL
1	NULL
ug	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
(	NULL
CRE	NULL
and	NULL
NF-Y	NULL
)	NULL
of	NULL
dA-dT	NULL
(	NULL
CCRE	NULL
)	NULL
and	NULL
radioactive	NULL
probe	NULL
(	NULL
0.1-1	NULL
ng	NULL
)	NULL
in	NULL
20	NULL
ul	NULL
of	NULL
the	NULL
same	NULL
buffer	NULL
.	NULL

Complexes	NULL
were	NULL
resolved	NULL
in	NULL
a	NULL
5	NULL
%	NULL
polyacrylamide	NULL
(	NULL
acrylamide	NULL
:	NULL
bisacrylamide	NULL
,	NULL
29:1	NULL
)	NULL
gel	NULL
run	NULL
in	NULL
0.25	NULL
x	NULL
TBE	NULL
at	NULL
4°C	NULL
.	NULL

Proliferation	NULL
assay	NULL
Purified	NULL
T	NULL
lymphocytes	NULL
were	NULL
grown	NULL
in	NULL
a	NULL
96-well	NULL
microtiter	NULL
plate	NULL
(	NULL
20	NULL
000	NULL
cells/well	NULL
)	NULL
in	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
200	NULL
ul	NULL
RPMI	NULL
References	NULL
Algarte	NULL
M	NULL
,	NULL
Lecine	NULL
P	NULL
,	NULL
Costello	NULL
R	NULL
,	NULL
Plet	NULL
A	NULL
,	NULL
Olive	NULL
D	NULL
and	NULL
Imbert	NULL
J	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
14	NULL
,	NULL
5060-5072	NULL
.	NULL

Barlat	NULL
I	NULL
,	NULL
Fesquet	NULL
D	NULL
,	NULL
Brechot	NULL
C	NULL
,	NULL
Henglein	NULL
B	NULL
,	NULL
Dupuy	NULL
DA	NULL
,	NULL
Vie	NULL
A	NULL
and	NULL
Blanchard	NULL
JM	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

Cell	NULL
Growth	NULL
Differ	NULL
.	NULL

,	NULL
4	NULL
,	NULL
105-113	NULL
.	NULL

Barlat	NULL
I	NULL
,	NULL
Henglein	NULL
B	NULL
,	NULL
Plet	NULL
A	NULL
,	NULL
Lamb	NULL
N	NULL
,	NULL
Fernandez	NULL
A	NULL
,	NULL
McKenzie	NULL
F	NULL
,	NULL
Pouyssegur	NULL
J	NULL
,	NULL
Vie	NULL
A	NULL
and	NULL
Blanchard	NULL
JM	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Oncogene	NULL
,	NULL
11	NULL
,	NULL
1309-1318	NULL
.	NULL

Cao	NULL
L	NULL
,	NULL
Faha	NULL
B	NULL
,	NULL
Dembski	NULL
M	NULL
,	NULL
Tsai	NULL
LH	NULL
,	NULL
Harlow	NULL
E	NULL
and	NULL
Dyson	NULL
N.	NULL
(	NULL
1992	NULL
)	NULL
.	NULL

Nature	NULL
,	NULL
355	NULL
,	NULL
176-179	NULL
.	NULL

Cardoso	NULL
MC	NULL
,	NULL
Leonhadt	NULL
H	NULL
and	NULL
Nadal	NULL
GB	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
74	NULL
,	NULL
979-992	NULL
.	NULL

Cerdan	NULL
C	NULL
,	NULL
Martin	NULL
Y	NULL
,	NULL
Brailly	NULL
H	NULL
,	NULL
Courcoul	NULL
M	NULL
,	NULL
Flavetta	NULL
S	NULL
,	NULL
Costello	NULL
R	NULL
,	NULL
Mawas	NULL
C	NULL
,	NULL
Birg	NULL
F	NULL
and	NULL
Olive	NULL
D.	NULL
(	NULL
1991	NULL
)	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
146	NULL
,	NULL
560-564	NULL
.	NULL

Costello	NULL
R	NULL
,	NULL
Lipcey	NULL
C	NULL
,	NULL
Algarte	NULL
M	NULL
,	NULL
Cerdan	NULL
C	NULL
,	NULL
Baeurle	NULL
PA	NULL
,	NULL
Olive	NULL
D	NULL
and	NULL
Imbert	NULL
J	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

Cell	NULL
Growth	NULL
Differ	NULL
.	NULL

,	NULL
4	NULL
,	NULL
329	NULL
339	NULL
.	NULL

1640	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
,	NULL
and	NULL
(	NULL
Amersham	NULL
,	NULL
0.05	NULL
uCi/well	NULL
)	NULL
added	NULL
at	NULL
the	NULL
indicated	NULL
times	NULL
for	NULL
18	NULL
h.	NULL
Cells	NULL
were	NULL
then	NULL
collected	NULL
on	NULL
Whatman	NULL
glass	NULL
filters	NULL
and	NULL
incorporated	NULL
radioactivity	NULL
estimated	NULL
by	NULL
liquid	NULL
scintillation	NULL
counting	NULL
.	NULL

All	NULL
assays	NULL
were	NULL
performed	NULL
in	NULL
triplicate	NULL
.	NULL

Antibodies	NULL
The	NULL
following	NULL
antibodies	NULL
were	NULL
used	NULL
for	NULL
T	NULL
lymphocyte	NULL
stimulation	NULL
:	NULL
mAb	NULL
39C1.5	NULL
and	NULL
6F10.3	NULL
(	NULL
anti	NULL
CD2	NULL
)	NULL
,	NULL
or	NULL
mAb	NULL
248	NULL
(	NULL
anti	NULL
CD28	NULL
)	NULL
.	NULL

CD2	NULL
mAb	NULL
was	NULL
used	NULL
purified	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
10	NULL
ug/ml	NULL
and	NULL
CD28	NULL
mAb	NULL
as	NULL
a	NULL
1/400	NULL
dilution	NULL
of	NULL
an	NULL
ascites	NULL
fluid	NULL
.	NULL

All	NULL
other	NULL
antibodies	NULL
were	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
.	NULL

CREB/ATF	NULL
,	NULL
mouse	NULL
monoclonal	NULL
25C10G	NULL
,	NULL
ATF-1	NULL
,	NULL
mouse	NULL
monoclonal	NULL
IgA	NULL
C41-5.1	NULL
;	NULL
CREB-1	NULL
and	NULL
CREM-1	NULL
,	NULL
rabbit	NULL
polyclonal	NULL
IgG	NULL
,	NULL
respectively	NULL
C-21	NULL
and	NULL
X-12	NULL
.	NULL

Protein	NULL
analysis	NULL
Proteins	NULL
were	NULL
obtained	NULL
by	NULL
direct	NULL
lysis	NULL
of	NULL
the	NULL
cells	NULL
in	NULL
Laemmili	NULL
's	NULL
loading	NULL
buffer	NULL
containing	NULL
6	NULL
mM	NULL
urea	NULL
and	NULL
equal	NULL
amounts	NULL
were	NULL
resolved	NULL
by	NULL
polyacrylamide	NULL
gel	NULL
electrophor-esis	NULL
.	NULL

After	NULL
transfer	NULL
onto	NULL
a	NULL
nitrocellulose	NULL
membrane	NULL
according	NULL
to	NULL
standard	NULL
procedures	NULL
,	NULL
immunodetection	NULL
was	NULL
carried	NULL
out	NULL
with	NULL
an	NULL
affinity-purified	NULL
rabbit	NULL
antibody	NULL
directed	NULL
against	NULL
a	NULL
bacterially	NULL
expressed	NULL
human	NULL
cyclin	NULL
A	NULL
(	NULL
Barlat	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
,	NULL
using	NULL
the	NULL
Amersham	NULL
chemilumines-cence	NULL
detection	NULL
system	NULL
.	NULL

Proteins	NULL
were	NULL
quantified	NULL
prior	NULL
to	NULL
electrophoresis	NULL
using	NULL
the	NULL
Bradford	NULL
assay	NULL
and	NULL
then	NULL
by	NULL
staining	NULL
the	NULL
membrane	NULL
with	NULL
Ponceau	NULL
red	NULL
.	NULL

Acknowledgements	NULL
We	NULL
are	NULL
grateful	NULL
to	NULL
C	NULL
Benoist	NULL
,	NULL
D	NULL
Mathis	NULL
and	NULL
R	NULL
Mantovani	NULL
for	NULL
their	NULL
generous	NULL
gift	NULL
of	NULL
NF-Y	NULL
antibodies	NULL
.	NULL

This	NULL
work	NULL
was	NULL
funded	NULL
by	NULL
institutional	NULL
grants	NULL
from	NULL
CNRS	NULL
,	NULL
INSERM	NULL
and	NULL
Université	NULL
Montpellier	NULL
II	NULL
,	NULL
as	NULL
well	NULL
as	NULL
by	NULL
contracts	NULL
from	NULL
Association	NULL
pour	NULL
la	NULL
Recherche	NULL
sur	NULL
le	NULL
Cancer	NULL
,	NULL
Ligue	NULL
Nationale	NULL
Contre	NULL
le	NULL
Cancer	NULL
and	NULL
Rhone-Poulenc	NULL
Rorer	NULL
.	NULL

XH	NULL
is	NULL
supported	NULL
by	NULL
the	NULL
Ligue	NULL
Nationale	NULL
contre	NULL
le	NULL
Cancer	NULL
and	NULL
AP	NULL
by	NULL
the	NULL
BIOMED2	NULL
programme	NULL
of	NULL
the	NULL
European	NULL
Community	NULL
.	NULL

Coustry	NULL
F	NULL
,	NULL
Maity	NULL
SN	NULL
and	NULL
de	NULL
Crombrugghe	NULL
B	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
270	NULL
,	NULL
468-475	NULL
.	NULL

D'Urso	NULL
G	NULL
,	NULL
Marraccino	NULL
RL	NULL
,	NULL
Marshak	NULL
DR	NULL
and	NULL
Roberts	NULL
JM	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
.	NULL

Science	NULL
,	NULL
250	NULL
,	NULL
786-791	NULL
.	NULL

Desdouets	NULL
C	NULL
,	NULL
Matesic	NULL
G	NULL
,	NULL
Molina	NULL
CA	NULL
,	NULL
Foulkes	NULL
NS	NULL
,	NULL
Sassone	NULL
CP	NULL
,	NULL
Brechot	NULL
C	NULL
and	NULL
Sobczak	NULL
TJ	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
15	NULL
,	NULL
3301-3309	NULL
.	NULL

Devoto	NULL
SH	NULL
,	NULL
Mudryj	NULL
M	NULL
,	NULL
Pines	NULL
J	NULL
,	NULL
Hunter	NULL
T	NULL
and	NULL
Nevins	NULL
JR.	NULL
(	NULL
1992	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
68	NULL
,	NULL
167-176	NULL
.	NULL

Dutta	NULL
A	NULL
and	NULL
Stillman	NULL
B	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
11	NULL
,	NULL
2189-2199	NULL
.	NULL

Garrity	NULL
PA	NULL
and	NULL
Wold	NULL
BJ	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
89	NULL
,	NULL
1021-1025	NULL
.	NULL

Helin	NULL
K	NULL
and	NULL
Harlow	NULL
E.	NULL
(	NULL
1993	NULL
)	NULL
.	NULL

Trends	NULL
Cell	NULL
Biol	NULL
.	NULL

,	NULL
3	NULL
,	NULL
43-46	NULL
.	NULL

Henglein	NULL
B	NULL
,	NULL
Chenivesse	NULL
X	NULL
,	NULL
Wang	NULL
J	NULL
,	NULL
Eick	NULL
D	NULL
and	NULL
Brechot	NULL
C.	NULL
(	NULL
1994	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
91	NULL
,	NULL
5490-5494	NULL
.	NULL

Hori	NULL
T	NULL
,	NULL
Uchiyama	NULL
T	NULL
,	NULL
Tsudo	NULL
M	NULL
,	NULL
Umadome	NULL
,	NULL
H	NULL
,	NULL
Ohno	NULL
H	NULL
,	NULL
Fukuhara	NULL
S	NULL
,	NULL
Kita	NULL
K	NULL
,	NULL
and	NULL
Uchino	NULL
H.	NULL
(	NULL
1987	NULL
)	NULL
.	NULL

Blood	NULL
,	NULL
70	NULL
,	NULL
1069-1072	NULL
.	NULL

Huet	NULL
X	NULL
,	NULL
Rech	NULL
J	NULL
,	NULL
Plet	NULL
A	NULL
,	NULL
Vié	NULL
A	NULL
and	NULL
Blanchard	NULL
JM	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
10	NULL
,	NULL
3789-3798	NULL
.	NULL

LaThangue	NULL
N.	NULL
(	NULL
1994	NULL
)	NULL
.	NULL

Trends	NULL
Biochem	NULL
.	NULL

Sci	NULL
.	NULL

,	NULL
19	NULL
,	NULL
108-114	NULL
.	NULL

Lehner	NULL
CF	NULL
and	NULL
O'Farrell	NULL
PH	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
56	NULL
,	NULL
957-968	NULL
.	NULL

Lehner	NULL
CF	NULL
and	NULL
O'Farrell	NULL
PH	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
61	NULL
,	NULL
535-547	NULL
.	NULL

Li	NULL
Y	NULL
,	NULL
Graham	NULL
C	NULL
,	NULL
Lacy	NULL
S	NULL
,	NULL
Duncan	NULL
AM	NULL
and	NULL
Whyte	NULL
P.	NULL
(	NULL
1993	NULL
)	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

,	NULL
7	NULL
,	NULL
2366-2377	NULL
.	NULL

Nevins	NULL
JR.	NULL
(	NULL
1992	NULL
)	NULL
.	NULL

Science	NULL
,	NULL
258	NULL
,	NULL
424-429	NULL
.	NULL

Olive	NULL
D	NULL
,	NULL
Pages	NULL
F	NULL
,	NULL
Klasen	NULL
S	NULL
,	NULL
Battifora	NULL
M	NULL
,	NULL
Costello	NULL
R	NULL
,	NULL
Nunes	NULL
J	NULL
,	NULL
Truneh	NULL
A	NULL
,	NULL
Ragueneau	NULL
M	NULL
,	NULL
Martin	NULL
Y	NULL
,	NULL
Imbert	NULL
J	NULL
,	NULL
Birg	NULL
F	NULL
,	NULL
Mawas	NULL
C	NULL
,	NULL
Bagnasco	NULL
M	NULL
and	NULL
Cerdan	NULL
C.	NULL
(	NULL
1994	NULL
)	NULL
.	NULL

Fundament	NULL
.	NULL

Clin	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
2	NULL
,	NULL
185-197	NULL
.	NULL

Pagano	NULL
M	NULL
,	NULL
Draetta	NULL
G	NULL
and	NULL
Jansen	NULL
DP	NULL
.	NULL

(	NULL
1992a	NULL
)	NULL
.	NULL

Science	NULL
,	NULL
255	NULL
,	NULL
1144-1147	NULL
.	NULL

Pagano	NULL
M	NULL
,	NULL
Pepperkok	NULL
R	NULL
,	NULL
Verde	NULL
F	NULL
,	NULL
Ansorge	NULL
W	NULL
and	NULL
Draetta	NULL
G.	NULL
(	NULL
1992b	NULL
)	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
11	NULL
,	NULL
961-971	NULL
.	NULL

Pines	NULL
J	NULL
and	NULL
Hunter	NULL
T.	NULL
(	NULL
19902	NULL
)	NULL
.	NULL

Nature	NULL
,	NULL
346	NULL
,	NULL
760-763	NULL
.	NULL

Pines	NULL
J	NULL
and	NULL
Hunter	NULL
T.	NULL
(	NULL
1990b	NULL
)	NULL
.	NULL

New	NULL
Biol	NULL
.	NULL

,	NULL
2	NULL
,	NULL
389-401	NULL
.	NULL

Resnitzky	NULL
D	NULL
,	NULL
Hengst	NULL
L	NULL
and	NULL
Reed	NULL
SI	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
15	NULL
,	NULL
4347-4352	NULL
.	NULL

Schulze	NULL
A	NULL
,	NULL
Zerfass	NULL
K	NULL
,	NULL
Spitkovsky	NULL
D	NULL
,	NULL
Middendorp	NULL
S	NULL
,	NULL
Berges	NULL
J	NULL
,	NULL
Helin	NULL
K	NULL
,	NULL
Jansen	NULL
DP	NULL
and	NULL
Henglein	NULL
B	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Nat/	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
92	NULL
,	NULL
11264-11268	NULL
.	NULL

Shirodkar	NULL
S	NULL
,	NULL
Ewen	NULL
M	NULL
,	NULL
DeCaprio	NULL
JA	NULL
,	NULL
Morgan	NULL
J	NULL
,	NULL
Livingston	NULL
DM	NULL
and	NULL
Chittenden	NULL
T.	NULL
(	NULL
1992	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
68	NULL
,	NULL
157-166	NULL
.	NULL

Cyclin	NULL
A	NULL
expression	NULL
in	NULL
human	NULL
primary	NULL
T	NULL
lymphocytes	NULL
A	NULL
Plet	NULL
et	NULL
al	NULL
Sobczak	NULL
TJ	NULL
,	NULL
Harper	NULL
F	NULL
,	NULL
Florentin	NULL
Y	NULL
,	NULL
Zindy	NULL
F	NULL
,	NULL
Brechot	NULL
C	NULL
and	NULL
Puvion	NULL
E.	NULL
(	NULL
1993	NULL
)	NULL
.	NULL

Exp	NULL
.	NULL

Cell	NULL
Res	NULL
.	NULL

,	NULL
206	NULL
,	NULL
43-48	NULL
.	NULL

Swenson	NULL
KI	NULL
,	NULL
Farrell	NULL
KM	NULL
and	NULL
Ruderman	NULL
JV	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
47	NULL
,	NULL
861-870	NULL
.	NULL

Tsai	NULL
LH	NULL
,	NULL
Harlow	NULL
E	NULL
and	NULL
Meyerson	NULL
M.	NULL
(	NULL
1991	NULL
)	NULL
.	NULL

Nature	NULL
,	NULL
353	NULL
,	NULL
174-177	NULL
.	NULL

Walker	NULL
RA	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
354	NULL
,	NULL
314-317	NULL
Weinberg	NULL
RA	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
81	NULL
,	NULL
323-330	NULL
.	NULL

Wright	NULL
KL	NULL
,	NULL
Vilen	NULL
BJ	NULL
,	NULL
Itoh-Lindstrom	NULL
Y	NULL
,	NULL
Criscitiello	NULL
M	NULL
,	NULL
Cogswell	NULL
P	NULL
,	NULL
Clarke	NULL
JB	NULL
and	NULL
Ting	NULL
JPY	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
13	NULL
,	NULL
4042-4053	NULL
.	NULL

Xiong	NULL
Y	NULL
,	NULL
Zhang	NULL
H	NULL
and	NULL
Beach	NULL
D.	NULL
(	NULL
1993	NULL
)	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

,	NULL
7	NULL
,	NULL
1572-1583	NULL
.	NULL

Xu	NULL
M	NULL
,	NULL
Sheppard	NULL
KA	NULL
,	NULL
Peng	NULL
CY	NULL
,	NULL
Yee	NULL
AS	NULL
and	NULL
Piwnica	NULL
WH	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
14	NULL
,	NULL
$	NULL
420-8431	NULL
.	NULL

Yoshizumi	NULL
M	NULL
,	NULL
Hsieh	NULL
CM	NULL
,	NULL
Zhou	NULL
F	NULL
,	NULL
Tsai	NULL
JC	NULL
,	NULL
Patterson	NULL
C	NULL
,	NULL
Perrella	NULL
MA	NULL
and	NULL
Lee	NULL
ME	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
15	NULL
,	NULL
3266-3272	NULL
.	NULL

Zwicker	NULL
J	NULL
,	NULL
Liu	NULL
N	NULL
,	NULL
Engeland	NULL
K	NULL
,	NULL
Lucibello	NULL
FC	NULL
and	NULL
Muller	NULL
R.	NULL
(	NULL
1996	NULL
)	NULL
.	NULL

Science	NULL
,	NULL
271	NULL
,	NULL
1595-1597	NULL
.	NULL

Zwicker	NULL
J	NULL
,	NULL
Lucibello	NULL
FC	NULL
,	NULL
Wolfraim	NULL
LA	NULL
,	NULL
Gross	NULL
C	NULL
,	NULL
Truss	NULL
M	NULL
,	NULL
Engeland	NULL
K	NULL
and	NULL
Muller	NULL
R.	NULL
(	NULL
1995	NULL
)	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
14	NULL
,	NULL
4514-4522	NULL
.	NULL

2583	NULL

